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This thesis describes studies in which the budding yeast Saccharomyces cerevisiae was 
used as a model organism for uncovering mechanisms underlying aging of eukaryotic 
cells. We identified lithocholic acid (LCA), a bile acid, as a natural compound that 
increases the chronological lifespan of yeast cultured under longevity-extending caloric 
restriction (CR) conditions by targeting lipid metabolism. Our findings revealed 
mechanisms by which LCA extends yeast chronological lifespan, drives the evolution of 
longevity regulation within ecosystems, and suppresses mitochondrial deficiency known 
to cause a neurological disorder in humans. We demonstrated that the age-dependent 
dynamics of the mitochondrial tubular network regulates longevity of chronologically 
aging yeast by modulating age-related apoptosis. This mitochondria-controlled form of 
programmed apoptotic death is elicited by the efflux of the pro-apoptotic proteins 
cytochrome c, Aif1p and Nuc1p from mitochondria in reproductively mature yeast cells 
that enter stationary growth phase; furthermore, this form of age-related apoptotic death 
depends on the metacaspase Yca1p. We provided evidence that the CR diet delays the 
fragmentation of the mitochondrial tubular network during early stationary phase. This, 
in turn, slows down the age-related exit of pro-apoptotic proteins from mitochondria, 
attenuates apoptotic cell death, and ultimately prolongs lifespan. Our findings also 
iv  
revealed that LCA further increases the chronological lifespan of CR yeast by preventing 
mitochondrial fragmentation during late stationary phase, thus averting the age-related 
exit of pro-apoptotic proteins from mitochondria and inhibiting programmed apoptotic 
cell death. Moreover, findings reported in this thesis imply that LCA extends longevity of 
chronologically aging yeast only if added at certain critical periods of their lifespan. 
Based on these findings, we propose a hypothesis of a biomolecular longevity network 
undergoing a stepwise progression through a series of checkpoints in chronologically 
aging yeast. In this thesis we also propose a hypothesis in which LCA - as well as other 
interspecies chemical signals released into the environment - create xenohormetic, 
hormetic and cytostatic selective forces driving the ecosystemic evolution of longevity 
regulation mechanisms. Moreover, findings described in this thesis suggest a previously 
unknown mechanism by which LCA suppresses mitochondrial deficiency causing the 
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The budding yeast Saccharomyces cerevisiae is a beneficial model for uncovering 
fundamental mechanisms and biological principles that underlie the complexity of 
cellular aging in multicellular eukaryotes [1 - 6]. This unicellular eukaryotic organism is 
amenable to comprehensive biochemical, genetic, cell biological, chemical biological, 
system biological and microfluidic dissection analyses [7 - 12]. Therefore, the use of S. 
cerevisiae as a model in aging research provided deep mechanistic insights into cellular 
processes that play key roles in regulating longevity of evolutionarily distant eukaryotic 
organisms. Because S. cerevisiae possesses relatively short and easily monitored 
chronological and replicative lifespans, this unicellular eukaryote played a key role in 
discovering: (1) many genes that control cellular aging and define organismal longevity 
not only in yeast but also in other eukaryotic organisms across species; (2) several crucial 
nutrient- and energy-sensing signaling pathways orchestrating an evolutionarily 
conserved compendium of longevity-defining cellular processes across phyla; and (3) 
some longevity-extending chemical compounds that slow down aging, improve health, 
attenuate age-related pathologies and delay the onset of age-related diseases in 
evolutionarily distant multicellular eukaryotic organisms [1 - 6, 13 - 22]. These studies 
provided comprehensive evidence that the signaling pathways orchestrating cellular 
aging and mechanisms of their fine-tuning by longevity-extending genetic, dietary and 
pharmacological interventions are conserved across species. 
Two different paradigms of yeast aging are known, each being investigated 
separately from each other with the help of robust assays. These assays are conducted 
under manageable laboratory conditions and have been automated to facilitate a systemic 
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analysis of the aging process in a high-throughput format [9, 10, 11, 12, 23 - 29]. In the 
chronological aging paradigm, yeast aging is defined by the length of time during which 
a cell remains viable after its growth and division have been arrested [24, 30, 31]. Yeast 
chronological aging under laboratory conditions is elucidated with the help of a simple 
clonogenic assay. The assay examines the proportion of yeast cells that in liquid cultures 
remain viable at different time points following entry of a cell population into the non- 
proliferative stationary phase; cell viability in the clonogenic assay is measured by 
monitoring the ability of a cell to form a colony on the surface of a solid nutrient-rich 
medium [3, 28, 30]. Chronological aging in yeast not only mimics aging of non-dividing, 
post-mitotic cells (such as neurons) in a multicellular eukaryotic organism but also 
provides a simple model for organismal aging [32, 33]. Replicative aging of yeast is 
defined by the maximum number of daughter cells that a mother cell can make before 
becoming senescent [26, 34, 35]. Because S. cerevisiae reproduces by asymmetric cell 
division, its replicative aging under laboratory conditions is elucidated using a 
micromanipulator to remove the budding progeny of a mother cell and counting the total 
number of asymmetric mitotic divisions the mother cell could undertake [26, 35]. Yeast 
replicative aging is believed to mimic aging of dividing, mitotically active cells (such as 
lymphocytes) within a multicellular eukaryotic organism [2, 32]. The use of vigorous 
assays for elucidating longevity regulation in chronologically or replicatively aging yeast 
under laboratory conditions has significantly advanced our understanding of cell- 
autonomous mechanisms underlying longevity-defining processes within an individual 
cell in eukaryotic organisms across phyla [1 - 3, 5, 6, 10]. 
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Moreover, studies in yeast also advanced fundamental knowledge about cell-non- 
autonomous mechanisms that regulate longevity. Such mechanisms operate within 
organized populations of yeast cells attached to solid surfaces to form a colony or a 
biofilm. Such cells: (1) communicate with each other and cells in surrounding colonies or 
biofilms; (2) age chronologically and replicatively; and (3) undergo spatially organized 
growth, differentiation, aging or death, depending on their position within the colony [4, 
36 - 43]. 
 
It needs to be emphasized that cell-autonomous and cell-non-autonomous 
intraspecies mechanisms regulating yeast longevity have evolved in the process of natural 
selection within an ecosystem [44 - 46]. It has been suggested that this process: (1) is 
orchestrated by ecosystemic, interspecies mechanisms of lifespan regulation acting within 
the ecosystem; and (2) is driven by the ability of yeast cells to undergo certain pro- 
survival changes to their metabolism and physiology in response to some chemical 
compounds that, after being released to the ecosystem by other groups of organisms, may 
trigger a hormetic and/or cytostatic response in yeast [44 - 48]. 
Aging of multicellular and unicellular eukaryotic organisms is a multifactorial 
biological phenomenon that has various causes and affects a number of cellular activities 
[1, 49]. These numerous activities are modulated by only a few nutrient- and energy- 
sensing signaling pathways that are conserved across phyla and include the 
insulin/insulin-like growth factor 1 (IGF-1), AMP-activated protein kinase/target of 
rapamycin (AMPK/TOR) and cAMP/protein kinase A (cAMP/PKA) pathways (Figure 
1.1) [1, 49 - 52]. By sharing a compendium of protein kinases and adaptor proteins, the 
insulin/IGF-1, AMPK/TOR and cAMP/PKA pathways in yeast, worms, fruit flies and 
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mammals converge into a network regulating longevity [50 - 54]. By sensing the 
nutritional status of the whole organism as well as the intracellular nutrient and energy 
status, functional state of mitochondria, and concentration of reactive oxygen species 
(ROS) produced in mitochondria, the longevity network regulates lifespan across species 







































Figure 1.1. The functional states of numerous longevity-defining processes and their 
spatiotemporal organization are modulated by only a few nutrient- and energy-sensing 
signaling pathways that are conserved across phyla and include the AMP-activated 
protein kinase/target of rapamycin (AMPK/TOR), cAMP/protein kinase A (cAMP/PKA) 
and insulin/insulin-like growth factor 1 (IGF-1) pathways (see text in section 1.2 for 
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details). Reproduced from Fontana, L., Partridge, L. and Longo, V.D. (2010). Extending 
healthy life span - from yeast to humans. Science 328:321-326. 
 
 
By defining the organismal and intracellular nutrient and energy status, nutrient 
intake plays an important role in modulating lifespan and influences age-related 
pathologies [55, 56]. Two dietary regimens are known to have the most profound 
longevity-extending effects across species and to improve overall health by delaying the 
onset of age-related diseases. They include: (1) caloric restriction (CR), a diet in which 
only calorie intake is reduced but the supply of amino acids, vitamins and other nutrients 
is not compromised [56 - 58]; and (2) dietary restriction (DR), in which the intake of 
nutrients (but not necessarily of calories) is reduced by limiting food supply without 
causing malnutrition [59 - 61]. In a “TOR-centric” view of longevity regulation, TOR 
 
alone governs the longevity-extending and health-improving effects of CR/DR by: (1) 
integrating the flow of information on the organismal and intracellular nutrient and 
energy status from the protein kinases AMPK, PKA, PKB/AKT (the insulin/IGF-1 
pathway) and ERK1/2 (the PKA-inhibited Raf/MEK/ERK protein kinase cascade) as well 
as from the mitochondrial redox protein P66Shc; (2) sensing the intracellular levels of 
amino acids in an AMPK-independent manner; and (3) operating as a control center 
which, based on the information it has gathered and processed, modulates many 
longevity-related processes in a sirtuin-independent fashion [62 - 64]. The inability of CR 
 
to increase the replicative lifespan (RLS) of yeast mutants lacking components of the 
TOR pathway [65] and the lack of the beneficial effect of DR on lifespan in worms with 
reduced TOR signaling [66, 67] support the proposed central role for TOR in 
orchestrating the longevity-extending effect of CR/DR in these two longevity paradigms. 
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Moreover, while the postulated by the TOR-centric model dispensability of sirtuins for 
the longevity benefit associated with DR has been confirmed in worms [67], the 
importance of the sirtuin Sir2p in mediating the longevity-extending effect of CR in 
replicatively aging yeast is debated [65, 68 - 70]. Noteworthy, while TOR is a central 
regulator of the longevity-extending effect of CR in replicatively aging yeast, the 
longevity benefit associated with CR in chronologically aging yeast is mediated by a 
signaling network that includes: (1) the TOR and cAMP/PKA pathways converged on 
Rim15p, which therefore acts as a nutritional integrator; and (2) some other, currently 
unknown pathways that are not centered on Rim15p [53]. Considering the likely 
convergence of the insulin/IGF-1, AMPK/TOR and cAMP/PKA signaling pathways into 
a network regulating longevity in worms, fruit flies and mammals (see above), it is 
feasible that - akin to TOR - the insulin/IGF-1 and cAMP/PKA pathways may contribute 
to the beneficial effect of CR/DR on their longevity. Although some findings in worms, 
fruit flies and mammals support the involvement of the insulin/IGF-1 pathway in the 
longevity benefit associated with CR/DR, other data imply that such benefit is 
independent of insulin/IGF-1 [51]. The role of cAMP/PKA signaling in the longevity- 
extending effect of CR/DR in these multicellular eukaryotes remains to be tested. 
Importantly, the recently reported in worms involvement of both independent and 
overlapping pathways in lifespan extension by different DR regimens [71] supports the 
notion that the longevity benefit associated with nutrient limitation is mediated by a 
signaling network that integrates several pathways. 
Akin to CR and DR regimens, certain pharmacological interventions can extend 
longevity across phyla and improve health by beneficially influencing age-related 
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pathologies. Noteworthy, all of the currently known anti-aging compounds increase 
lifespan under non-CR or non-DR conditions. Under such conditions, these compounds 
have been shown to: (1) provide the longevity and health benefits associated with CR and 
DR, but without restricting caloric and nutrient intake; and (2) mimic numerous 
longevity-extending effects of CR and DR on gene expression pattern, metabolic and 
 
physiological  processes, and stress response pathways. Therefore, the names “CR 
 
mimetics” and “DR mimetics” have been coined for them [72, 73]. 
 
Importantly, most CR mimetics and DR mimetics target signaling pathways that 
modulate longevity in response to the organismal and intracellular nutrient and energy 
status, including the insulin/IGF-1 and AMPK/TOR pathways as well as the sirtuin- 
governed protein deacetylation module of the longevity signaling network integrating 
these pathways [14]. Furthermore, such compounds as resveratrol, metformin and 
mianserin increase lifespan only under non-CR or non-DR conditions, but are unable to 
do so if the supply of calories or nutrients is limited [47, 74 - 77]. Hence, one could 
envision that most, if not all, longevity pathways are “adaptable” by nature, i.e., that they 
 
modulate longevity only in response to certain changes in the extracellular and 
intracellular nutrient and energy status of an organism. However, Li+ in worms and 
rapamycin in fruits flies extend lifespan even under DR conditions [78, 79]. It is likely 
therefore that some longevity pathways could be ʺconstitutiveʺ or ʺhousekeepingʺ by 
nature, i.e., that they: (1) modulate longevity irrespective of the organismal and 
 
intracellular nutrient and energy status; and (2) do not overlap (or only partially overlap) 
with the adaptable longevity pathways that are under the stringent control of calorie 
and/or nutrient availability. The challenge is to identify such housekeeping longevity 
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pathways, perhaps by using a chemical screen for compounds that can extend longevity 
even under CR/DR conditions. Because under such conditions the adaptable pro-aging 
pathways are fully suppressed and the adaptable anti-aging pathways are fully activated, 
a compound that can increase lifespan is expected to target the housekeeping longevity 
pathways. 
Noteworthy, two anti-aging compounds alter lipid levels in mammals and fruit flies 
under non-DR conditions. Indeed, resveratrol treatment reduces the levels of the neutral 
lipids triacylglycerols (TAG) and increases free fatty acid (FFA) levels in mouse 
adipocytes [80]. Furthermore, feeding rapamycin to fruit flies results in elevated TAG 
levels [79]. Although it remains to be seen if such effects of resveratrol and rapamycin on 
lipid levels play a casual role in their anti-aging action under non-DR conditions, it 
should be stressed that lipid metabolism has been shown to be involved in longevity 
regulation in yeast [24, 81], worms [82 - 85], fruit flies [83, 86] and mice [80, 83, 87 - 
90]. We recently proposed a mechanism linking yeast longevity and lipid dynamics in the 
endoplasmic reticulum (ER), lipid droplets and peroxisomes. In this mechanism, a CR 
diet extends yeast chronological lifespan (CLS) by activating FFA oxidation in 
peroxisomes [24, 81, 91 - 93]. We expected that the identification of small molecules 
targeting this mechanism could yield novel anti-aging compounds. Such compounds can 
be used as research tools for defining the roles for different longevity pathways in 
modulating lipid metabolism and in integrating lipid dynamics with other longevity- 
related processes. Furthermore, the availability of such compounds would enable a quest 
for housekeeping longevity assurance pathways that do not overlap (or only partially 
overlap) with the adaptable TOR and cAMP/PKA pathways. Moreover, such compounds 
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would have a potential to be used as pharmaceutical agents for increasing lifespan and 
promoting healthy aging by delaying the onset of age-related diseases, regardless of an 
organism’s dietary regimen. 
 
We therefore conducted a high-throughput chemical genetic screen aimed at 
identifying small molecules that increase the CLS of yeast under CR conditions by 
targeting lipid metabolism and modulating housekeeping longevity assurance pathways. 
Our screen identified lithocholic acid (LCA), a bile acid, as one of such small molecules 
[14]. This thesis describes studies that led to the identification of some of the mechanisms 
through which LCA extends yeast chronological lifespan, drives the evolution of 
longevity regulation within ecosystems and suppresses mitochondrial deficiency known 





1.2 Thesis outline and contributions of colleagues 
 
Chapter 2 of this thesis outlines our evidence that the age-dependent dynamics of 
the mitochondrial tubular network regulates longevity of chronologically aging yeast by 
modulating age-related apoptosis. This mitochondria-controlled form of programmed 
apoptotic death is elicited by the efflux of the pro-apoptotic proteins cytochrome c, Aif1p 
and Nuc1p from mitochondria in reproductively mature yeast cells that enter stationary 
growth phase; furthermore, this form of age-related apoptotic death depends on the 
metacaspase Yca1p. Findings described in Chapter 2 provide evidence that the CR diet 
delays the fragmentation of the mitochondrial tubular network during early stationary 
phase. This, in turn, slows down the age-related exit of pro-apoptotic proteins from 
mitochondria, attenuates apoptotic cell death, and ultimately prolongs lifespan. Findings 
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described in Chapter 2 also revealed that LCA further increases the chronological 
lifespan of CR yeast by preventing mitochondrial fragmentation during late stationary 
phase, thus averting the age-related exit of pro-apoptotic proteins from mitochondria and 
inhibiting programmed apoptotic cell death. 
Findings reported in Chapter 3 of this thesis imply that LCA extends longevity of 
chronologically aging yeast only if added at certain critical periods of their lifespan. 
Based on these findings, we propose a hypothesis of a biomolecular longevity network 
undergoing a stepwise progression through a series of checkpoints in chronologically 
aging yeast. 
Findings reported in Chapter 4 of this thesis provide evidence that LCA enters 
yeast cells, accumulates mainly in the inner mitochondrial membrane, and elicits a 
remodeling of phospholipid synthesis and movement within both mitochondrial 
membranes. Such remodeling of mitochondrial phospholipid dynamics causes changes in 
mitochondrial membrane lipidome. These changes in the composition of membrane 
phospholipids alter mitochondrial abundance and morphology, thereby triggering 
changes in the age-related chronology of several longevity-defining redox processes 
confined to mitochondria. 
In Chapter 5 of this thesis we propose a hypothesis in which LCA - as well as other 
interspecies chemical signals released into the environment - create xenohormetic, 
hormetic and cytostatic selective forces driving the ecosystemic evolution of longevity 
regulation mechanisms. 
Findings described in Chapter 6 of this thesis suggest a previously unknown 
mechanism by which LCA suppresses mitochondrial deficiency causing the late-onset 
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Leigh syndrome, a severe neurological disorder in humans. 
 
All findings described in Chapter 2 are presented in the manuscript of a paper that is 
currently in preparation for submission to Aging Cell. I expect this manuscript to be 
submitted for publication in October 2014. I carried out and supervised more than 70% of 
the work described in this manuscript and prepared its first draft. Dr. V. Titorenko 
provided intellectual leadership of this project and is currently editing the first draft of the 
manuscript. 
All findings described in Chapter 3 have been published in Cell Cycle [Burstein 
MT, Kyryakov P, Beach A, Richard VR, Koupaki O, Gomez-Perez A, Leonov A, Levy 
S, Noohi F, Titorenko VI (2012). Lithocholic acid extends longevity of chronologically 
aging yeast only if added at certain critical periods of their lifespan. Cell Cycle 11:3443- 
3462]. I carried out and supervised more than 60% of the work described in this 
publication and prepared the first draft of the entire manuscript. Dr. V. Titorenko 
provided intellectual leadership of this project and edited the first draft of the manuscript. 
All findings described in Chapter 4 have been published in Redox Biol [Burstein 
MT, Titorenko VI (2014). A mitochondrially targeted compound delays aging in yeast 
through a mechanism linking mitochondrial membrane lipid metabolism to mitochondrial 
redox biology. Redox Biol 2:305-307]. I prepared the first draft of the entire manuscript. 
Dr. V. Titorenko provided intellectual leadership of this project and edited the first draft 
of the manuscript. 
 
All findings described in Chapter 5 have been published in Dose Response 
[Burstein MT, Beach A, Richard VR, Koupaki O, Gomez-Perez A, Goldberg AA, 
Kyryakov P, Bourque SD, Glebov A, Titorenko VI (2012). Interspecies Chemical Signals 
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Released into the Environment May Create Xenohormetic, Hormetic and Cytostatic 
Selective Forces that Drive the Ecosystemic Evolution of Longevity Regulation 
Mechanisms. Dose Response 1075-1082]. I prepared the first draft of the entire 
manuscript. Dr. V. Titorenko provided intellectual leadership of this project and edited 
the first draft of the manuscript. 
All findings described in Chapter 6 are presented in the manuscript of a paper that 
is currently in preparation for submission to eLife. I expect this manuscript to be 
submitted for publication in September 2014. I carried out all of the work described in 
this manuscript and prepared its first draft. Dr. V. Titorenko provided intellectual 
leadership of this project and is currently editing the first draft of the manuscript. 
All abbreviations, citations, and the numbering of figures and tables that have been 
used in the published papers and in the manuscripts in preparation have been changed to 
the format of this thesis. 
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2 Age-dependent dynamics of the mitochondrial tubular network regulates 
longevity of chronologically aging yeast by modulating a mitochondria- 






One of the early events of apoptosis in mammalian cells is the fragmentation of 
their interconnected tubular mitochondria [94 - 96]. Such fragmentation is known to be 
driven by the coordinated action of the mitochondrial fission and fusion machines, whose 
protein components control the efflux of cytochrome c and several other pro-apoptotic 
proteins from the mitochondrial intermembrane space [96]. The release of these pro- 
apoptotic proteins from mitochondria triggers caspase activation and nuclear DNA 
cleavage [97, 98]. Yeast cells also undergo apoptosis [99]. Their short-term exposure to 
hydrogen peroxide, acetic acid, hyperosmotic stress or α pheromone causes apoptotic cell 
death [100, 101] that has been linked to mitochondrial fragmentation, mitochondrial outer 
membrane permeabilization, and the release of several intermembrane space proteins 
from mitochondria [102 - 108]. The exit of the apoptosis inducing factor Aif1p and 
endonuclease G (Nuc1p) from yeast mitochondria and their subsequent import into the 
nucleus trigger such exogenously induced apoptosis by promoting DNA cleavage [104, 
107] (Figure 2.1). Another intermembrane space protein that is released from yeast 
mitochondria during exogenously induced apoptosis is cytochrome c [102, 105, 109]. 
Although some data suggest that - akin to its essential role in triggering the apoptotic 
caspase cascade in mammalian cells [98] - cytochrome c in the cytosol of yeast cells 
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activates the metacaspase Yca1p [102, 105, 110 - 112], the involvement of cytosolic 






Figure 2.1. The basic molecular machinery of yeast apoptosis. From: Carmona-Gutierrez 
D, Madeo F (2006). Yeast unravels epigenetic apoptosis control: deadly chat within a 




Importantly, chronologically aging yeast die, in an Aif1p-, Nuc1p- and Yca1p- 
dependent fashion, exhibiting characteristic markers of apoptosis such as chromatin 
condensation, nuclear fragmentation, DNA cleavage, phosphatidylserine (PS) 
externalization, ROS production, and caspase activation [104, 107, 114 - 117]. Thus, the 
chronological aging of yeast is linked to an apoptosis-like programmed cell death [118 - 
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121]. This age-related apoptotic cell death is induced in response to presently unknown 
endogenous stimuli, somehow controlled by mitochondria (perhaps, through the release 
of pro-apoptotic proteins from the mitochondrial intermembrane space), and governed by 
yet-to-be-identified mechanisms. In studies described in this chapter of the thesis, we 




2.2 Materials and Methods 
 
Strains and media 
 
 
The wild-type strain Saccharomyces cerevisiae BY4742 (MAT α his3∆1 leu2∆0 lys2∆0 
ura3∆0) and mutant strains fis1∆ (MAT α his3∆1 leu2∆0 lys2∆0 ura3∆0 fis1∆::kanMX4), 
dnm1∆ (MAT α his3∆1 leu2∆0 lys2∆0 ura3∆0 dnm1∆::kanMX4), mdv1∆ (MAT α his3∆1 
leu2∆0 lys2∆0 ura3∆0 mdv1∆::kanMX4), caf4∆ (MAT α his3∆1 leu2∆0 lys2∆0 ura3∆0 
caf4∆::kanMX4), fzo1∆ (MAT α his3∆1 leu2∆0 lys2∆0 ura3∆0 fzo1∆::kanMX4), ugo1∆ 
(MAT α his3∆1 leu2∆0 lys2∆0 ura3∆0 ugo1∆::kanMX4), mgm1∆ (MAT α his3∆1 leu2∆0 
lys2∆0 ura3∆0 mgm1∆::kanMX4), mdm30∆ (MAT α his3∆1 leu2∆0 lys2∆0 ura3∆0 
mdm30∆::kanMX4), pcp1∆ (MAT α his3∆1 leu2∆0 lys2∆0 ura3∆0 pcp1∆::kanMX4), 
aif1∆ (MAT α his3∆1 leu2∆0 lys2∆0 ura3∆0 aif1∆::kanMX4), nuc1∆ (MAT α his3∆1 
leu2∆0 lys2∆0 ura3∆0 nuc1∆::kanMX4), yca1∆ (MAT α his3∆1 leu2∆0 lys2∆0 ura3∆0 
yca1∆::kanMX4), cyt1∆ (MAT α his3∆1 leu2∆0 lys2∆0 ura3∆0 cyt1∆::kanMX4), rip1∆ 
(MAT α his3∆1 leu2∆0 lys2∆0 ura3∆0 rip1∆::kanMX4), bcs1∆ (MAT α his3∆1 leu2∆0 
lys2∆0 ura3∆0 bcs1∆::kanMX4), cox5A∆ (MAT α his3∆1 leu2∆0 lys2∆0 ura3∆0 
cox5A∆::kanMX4), cox8∆ (MAT α his3∆1 leu2∆0 lys2∆0 ura3∆0 cox8∆::kanMX4), 
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pet100∆ (MAT α his3∆1 leu2∆0 lys2∆0 ura3∆0 pet100∆::kanMX4), aco1∆ (MAT α his3∆1 
leu2∆0 lys2∆0 ura3∆0 aco1∆::kanMX4), kgd1∆ (MAT α his3∆1 leu2∆0 lys2∆0 ura3∆0 
kgd1∆::kanMX4), mdh1∆ (MAT α his3∆1 leu2∆0 lys2∆0 ura3∆0 mdh1∆::kanMX4), sod1∆ 
(MAT α his3∆1 leu2∆0 lys2∆0 ura3∆0 sod1∆::kanMX4), sod2∆ (MAT α his3∆1 leu2∆0 
lys2∆0 ura3∆0 sod2∆::kanMX4), ctt1∆ (MAT α his3∆1 leu2∆0 lys2∆0 ura3∆0 
ctt1∆::kanMX4) and cta1∆ (MAT α his3∆1 leu2∆0 lys2∆0 ura3∆0 cta1∆::kanMX4) were 
used in this study. Media components were as follows: (1) YEPD (0.2% glucose), 1% 
yeast extract, 2% peptone, 0.2% glucose; and (2) YEPD (2% glucose), 1% yeast extract, 





A plating assay for the analysis of chronological lifespan 
 
 
Cells were grown in YEPD (0.2% glucose) medium at 30oC with rotational shaking at 
 
200 rpm in Erlenmeyer flasks at a flask volume/medium volume ratio of 5:1. A sample of 
cells was removed from each culture at various time points. A fraction of the cell sample 
was diluted in order to determine the total number of cells per ml of culture using a 
hemacytometer. 10 μ l of serial dilutions (1:10 to 1:103) of cells were applied to the 
hemacytometer, where each large square is calibrated to hold 0.1 μ l. The number of cells 
in 4 large squares was then counted and an average was taken in order to ensure greater 
accuracy. The concentration of cells was calculated as follows: number of cells per large 
square x dilution factor x 10 x 1,000 = total number of cells per ml of culture. A second 
fraction of the cell sample was diluted and serial dilutions (1:102 to 1:105) of cells were 
 
plated onto YEPD (2% glucose) plates in triplicate in order to count the number of viable 
17  
cells per ml of each culture. 100 μ l of diluted culture was plated onto each plate. After a 
 
48-h incubation at 30oC, the number of colonies per plate was counted. The number of 
colony forming units (CFU) equals to the number of viable cells in a sample. Therefore, 
the number of viable cells was calculated as follows: number of colonies x dilution factor 
x 10 = number of viable cells per ml. For each culture assayed, % viability of the cells 
was calculated as follows: number of viable cells per ml / total number of cells per ml x 
100%. The % viability of cells in mid-logarithmic phase was set at 100% viability for that 
particular culture. The life span curves for wild-type and some of the mutant strains were 
also validated using a LIVE/DEAD yeast viability kit (Invitrogen) following the 




Monitoring the formation of reactive oxygen species (ROS) 
 
Wild-type and mutant cells grown in YEPD (0.2% glucose) were tested microscopically 
for the production of ROS by incubation with dihydrorhodamine 123 (DHR). In the cell, 
this nonfluorescent compound can be oxidized to the fluorescent chromophore rhodamine 
123 by ROS. Cells were also probed with a fluorescent counterstain Calcofluor White 
M2R (CW), which stains the yeast cell walls fluorescent blue. CW was added to each 
sample in order to label all cells for their proper visualization. DHR was stored in the 
dark at –20oC as 50 μ l aliquots of a 1 mg/ml solution in ethanol. CW was stored in the 
dark at –20oC as the 5 mM stock solution in anhydrous DMSO (dimethylsulfoxide). The 
 
concurrent staining of cells with DHR and CW was carried out as follows. The required 
amounts of the 50 μ l DHR aliquots (1 mg/ml) and of the 5 mM stock solution of CW 
were taken out of the freezer and warmed to room temperature. The solutions of DHR 
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and CW were then centrifuged at 21,000 x g for 5 min in order to clear them of any 
aggregates of fluorophores. For cell cultures with a titre of ~ 107 cells/ml, 100 μ l was 
taken out of the culture to be treated. If the cell titre was lower, proportionally larger 
volumes were used. 6 μ l of the 1 mg/ml DHR and 1 μ l of the 5 mM CW solutions 
were added to each 100 μ l aliquot of culture. After a 2-h incubation in the dark at room 
temperature, the samples were centrifuged at 21,000 x g for 5 min. Pellets were 
resuspended in 10 μ l of PBS buffer (20 mM KH2PO4/KOH, pH 7.5, and 150 mM 
NaCl). Each sample was then supplemented with 5 μ l of mounting medium, added to a 
microscope slide, covered with a coverslip, and sealed using nail polish. Once the slides 
were prepared, they were visualized under the Zeiss Axioplan fluorescence microscope 
mounted with a SPOT Insight 2 megapixel color mosaic digital camera. Several pictures 
of the cells on each slide were taken, with two pictures taken of each frame. One of the 
two pictures was of the cells seen through a rhodamine filter in order to detect cells 
dyed with DHR. The second picture was of the cells seen through a DAPI filter in order 
to visualize CW, and therefore all the cells present in the frame. For evaluating the 
percentage of DHR-positive cells, the UTHSCSA Image Tool (Version 3.0) software 
was used to calculate both the total number of cells and the number of stained cells. 
Fluorescence of individual DHR-positive cells in arbitrary units was determined by 
using the UTHSCSA Image Tool software (Version 3.0). In each of 3-5 independent 
experiments, the value of median fluorescence was calculated by analyzing at least 800- 
1000 cells that were collected at each time point. The median fluorescence values were 
plotted as a function of the number of days cells were cultured. 
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Monitoring the mitochondrial membrane potential (∆ψ) 
 
Rhodamine 123 (R123) (Invitrogen) staining for monitoring the mitochondrial membrane 
potential (∆ψ) was performed according to established procedure (Invitrogen manual for 
the Yeast Mitochondrial Stain Sampler Kit). Images were collected with a Zeiss Axioplan 
fluorescence microscope (Zeiss) mounted with a SPOT Insight 2 megapixel color mosaic 
digital camera (Spot Diagnostic Instruments). For evaluating the percentage of R123- 
positive cells, the UTHSCSA Image Tool (Version 3.0) software was used to calculate 
both the total number of cells and the number of stained cells. Fluorescence of individual 
R123-positive cells in arbitrary units was determined by using the UTHSCSA Image 
Tool software (Version 3.0). In each of 3-6 independent experiments, the value of median 
fluorescence was calculated by analyzing at least 800-1000 cells that were collected at 
each time point. The median fluorescence values were plotted as a function of the number 





Cell cultures were fixed in 3.7% formaldehyde for 45 min at room temperature. The cells 
were washed in solution B (100 mM KH2PO4/KOH pH 7.5, 1.2 M sorbitol), treated with 
Zymolyase 100T (MP Biomedicals, 1 μg Zymolyase 100T/1 mg cells) for 30 min at 30oC 
 
and then processed as previously described [122]. Monoclonal antibody raised against 
porin (Invitrogen, 0.25 μg/μl in TBSB buffer [20 mM Tris/HCl pH 7.5, 150 mM NaCl, 1 
mg/ml BSA]) was used as a primary antibody. Alexa Fluor 568 goat anti-mouse IgG 
(Invitrogen, 2 μg/μl in TBSB buffer) was used as a secondary antibody. The labeled 
samples were mounted in mounting solution (16.7 mM Tris/HCl pH 9.0, 1.7 mg/ml p- 
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phenylenediamine, 83% glycerol). Images were collected with a Zeiss Axioplan 
fluorescence microscope (Zeiss) mounted with a SPOT Insight 2 megapixel color mosaic 




Oxygen consumption assay 
 
The rate of oxygen consumption by yeast cells recovered at various time points was 
measured continuously in a 2-ml stirred chamber using a custom-designed biological 
oxygen monitor (Science Technical Center of Concordia University) equipped with a 
Clark-type oxygen electrode. 1 ml of YEPD medium supplemented with 0.2% glucose 
was added to the electrode for approximately 5 minutes to obtain a baseline. Cultured 
cells of a known titre were spun down at 3,000 x g for 5 minutes. The resulting pellet was 
resuspended in YEPD medium supplemented with 0.2% glucose and then added to the 
electrode with the medium that was used to obtain a baseline. The resulting slope was 




Pharmacological manipulation of chronological lifespan 
 
Chronological lifespan analysis was performed as described above in this section. The 
lithocholic (LCA) [#L6250] bile acid was from Sigma. The stock solution of LCA in 
DMSO was made on the day of adding this compound to cell cultures. LCA was added to 
growth medium at the final concentration of 50 µM immediately following cell 
inoculation into the medium. The final concentration of DMSO in yeast cultures 
supplemented with LCA (and in the corresponding control cultures supplemented with 




Cell viability assay for monitoring the susceptibility of yeast to an apoptotic mode of 
cell death induced by hydrogen peroxide 
A sample of cells was taken from a culture at a certain time-point. A fraction of the 
sample was diluted in order to determine the total number of cells using a 
hemacytometer. 2 × 107 cells were harvested by centrifugation for 1 min at 21,000 × g at 
room temperature and resuspended in 2 ml of YP medium containing 0.2% glucose as 
carbon source. Each cell suspension was divided into 2 equal aliquots. One aliquot was 
supplemented with hydrogen peroxide (#H325-500; Fisher Scientific) to the final 
concentration of 2.5 mM, whereas other aliquot remained untreated. Both aliquots were 
then incubated for 2 h at 30oC on a Labquake rotator (#400110; Thermolyne/Barnstead 
International) set for 360o rotation. Serial dilutions of cells were plated in duplicate onto 
 
plates containing YP medium with 2% glucose as carbon source. After 2 d of incubation 
 
at 30oC, the number of colony forming units (CFU) per plate was counted. The number of 
CFU was defined as the number of viable cells in a sample. For each aliquot of cells 
exposed to hydrogen peroxide, the % of viable cells was calculated as follows: (number 
of viable cells per ml in the aliquot exposed to hydrogen peroxide/number of viable cells 






Statistical analysis was performed using Microsoft Excel’s (2010) Analysis ToolPack- 
VBA. All data are presented as mean ± SEM. The p values were calculated using an 







2.3.1 Elucidating mechanisms that underlie characteristic changes in mitochondrial 
morphology and function taking place in chronologically aging yeast 
We found that mitochondria in CR yeast entering the non-proliferative stationary (ST) 
phase exist as a tubular network, whereas in quiescent non-CR yeast this network is fragmented 
into individual mitochondria (Figure 2.2). It is known that the morphology of mitochondria 
depends on a balance between the processes of mitochondrial fission, 
fusion and tubulation [123 - 125] (Figure 2.3). Of note, we demonstrated that the dnm1∆, 
 
 
mdv1∆ and caf4∆ mutations - all of which promote the formation of net-like mitochondria (Figure 
2.4) by eliminating components of the mitochondrial fission machine [123] (Figure 2.5) - extend 
the lifespan of CR yeast (Figure 2.6). Conversely, the fzo1∆, ugo1∆, mgm1∆, mdm30∆ and pcp1∆ 
mutations - all of which cause the accumulation of fragmented mitochondria (Figure 2.4) by 
eliminating components of the outer or inner membrane fusion machine [123] (Figure 2.7) - 
shorten the lifespan of yeast under CR (Figure 2.8). Furthermore, although the fis1∆ mutation 
eliminates an essential component of the mitochondrial fission machine (Figure 2.5), it impairs 
mitochondrial fission only in healthy, exponentially growing yeast cells [123, 124]. By contrast, 
fis1∆ does not abolish mitochondrial fission during exogenously induced apoptosis [126] and, akin 
to mutations that impair mitochondrial fusion, accelerates mitochondrial fragmentation in aging 
yeast under CR (Figure 2.4). Importantly, we found that the accumulation of fragmented 
mitochondria in the fis1∆ mutant coincides with its shortened chronological lifespan (Figure 2.9). 
Based on all these findings, we hypothesize that the ability of yeast cells that enter a non-
proliferative state under CR conditions to maintain a network appearance of mitochondria is 








Figure 2.2. Mitochondria in yeast cells entering the non-proliferative stationary (ST) 
phase under CR conditions exist as a tubular network, whereas in quiescent yeast cells 
under non-CR conditions the network is fragmented into individual mitochondria. 
Mitochondria were visualized by indirect immunofluorescence microscopy using 




Figure 2.3. Morphology of mitochondria depends on a balance between the processes of 
mitochondrial fission, fusion and tubulation. From: Okamoto K, Shaw JM (2005). 
Mitochondrial morphology and dynamics in yeast and multicellular eukaryotes. Annu 
Rev Genet 39:503-536. 
 
 
Figure 2.4. Morphology of mitochondria in wild-type cells and in mutant cells lacking 
individual components of the mitochondrial fission, fusion or tubulation machine. 
Mitochondria were visualized by indirect immunofluorescence microscopy using 




Figure 2.5. The spatiotemporal dynamics of proteins that compose the mitochondrial 






Figure 2.6. The dnm1∆, mdv1∆ and caf4∆ mutations – all of which promote the 
formation of net-like mitochondria by eliminating components of the mitochondrial 










Figure 2.7. Two mitochondrial fusion machines serve the sequential fusion of the outer 
mitochondrial membranes (OM) and the inner mitochondrial membranes (IM). 
Localization, topology, interaction, processing and degradation of proteins that compose 
two machines serving the sequential fusion of the OM and the IM. Tethering of the 








Figure 2.8. The fzo1∆, ugo1∆, mgm1∆, mdm30∆ and pcp1∆ mutations – all of which 
cause the accumulation of fragmented mitochondria by eliminating components of the 
outer or inner mitochondrial membrane fusion machine – shorten yeast chronological 






Figure 2.9. Akin to mutations that impair mitochondrial fusion, fis1 accelerates 
mitochondrial fragmentation in yeast cells grown under CR conditions and shortens their 
chronological lifespan. 
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We found that the tubular mitochondrial network undergoes fragmentation and is 
eventually converted to large spheres even in wild-type cells grown under CR conditions, 
particularly when these cells progress further into ST phase (Figure 2.10). Importantly, 
the potent anti-aging compound LCA - a bile acid which extends the chronological 
lifespan of wild-type strain under CR conditions [14] - prevents such fragmentation of the 
mitochondrial network and averts its conversion to large spheres (Figure 2.11). We 
demonstrated that LCA is unable to extend the chronological lifespans of the fzo1∆ and 
ugo1∆ mutant strains grown under CR conditions (Figures 2.12 and 2.14). By eliminating 
essential interacting components of the outer membrane fusion machine (Figure 2.7) 
[124, 127], the fzo1∆ and ugo1∆ mutations are known to cause the accumulation of 
fragmented mitochondria (Figure 2.4). The interaction between Fzo1p and Ugo1p has 
been shown to be essential for mitochondrial outer membrane fusion [123, 128]. It seems 
that the outer membrane GTPase Fzo1p initiates such fusion by forming an oligomeric 
complex in cis and in trans, thereby tethering outer membranes of two opposing 
mitochondria and bringing them into a docked state [124] (Figure 2.7). In addition to 
being essential for tethering of the mitochondrial outer membranes, both Fzo1p and 
Ugo1p are known to function, by a yet-to-be-identified mechanism, in merging of their 
lipid bilayers [127, 129]. 
Importantly, we revealed that, although LCA does not extend the chronological 
lifespans of fzo1∆ and ugo1∆, it increases the lifespans of chronologically aging mutants 
lacking other components of the outer (i.e., Mdm30p) or inner (i.e., Mgm1p and Pcp1p) 
membrane fusion machines (Figures 2.13 and 2.14). Thus, it is conceivable that LCA 
extends longevity of wild-type yeast by targeting Fzo1p and Ugo1p in the outer 
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membranes of fusion partners (Figure 2.15). We hypothesize that, by promoting the 
ability of Fzo1p and Ugo1p to tether and fuse the opposing mitochondrial outer 
membranes in wild-type cells, LCA prevents fragmentation of the mitochondrial network 
during late ST phase (Figure 2.11) due to its ability to shift a balance between the 
opposing processes of mitochondrial fission and fusion towards fusion. Hence, it is 
plausible that LCA extends the chronological lifespan of wild-type yeast under CR 
conditions in part by preserving the tubular mitochondrial network late in ST phase. 
 
 
Figure 2.10. In chronologically aging wild-type cells that enter a non-proliferative state, 
CR diet delays the fragmentation of the tubular mitochondrial network. During late ST 
phase, CR diet promotes the conversion of fragmented mitochondria to large spheres. 
Mitochondria were visualized by indirect immunofluorescence microscopy using 
monoclonal anti-porin primary antibodies. The percentage of cells exhibiting the network 
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of long mitochondrial tubules, fragmented mitochondria or large spherical mitochondria 
was calculated. At least 600 cells were used for quantification of mitochondrial 
morphology at each time point. Data are presented as mean ± SEM (n = 3). Cells were 






Figure 2.11. In chronologically aging wild-type cells grown under CR conditions, LCA 
prevents both the fragmentation of the tubular mitochondrial network and the 
accumulation of large spheres. Mitochondria were visualized by indirect 
immunofluorescence microscopy using monoclonal anti-porin primary antibodies. The 
percentage of cells exhibiting the network of long mitochondrial tubules, fragmented 
mitochondria or large spherical mitochondria was calculated. At least 600 cells were used 
for quantification of mitochondrial morphology at each time point. Data are presented as 




Figure 2.12. LCA does not extend the chronological lifespans of the fzo1∆ and ugo1∆ 
 







Figure 2.13. Although LCA does not extend the chronological lifespans of the fzo1∆ and 
 
 
ugo1∆ mutants, it increases the chronological lifespans of mutants lacking other 
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Figure 2.14. Although LCA does not extend the mean chronological lifespans of the 
fzo1∆ and ugo1∆ mutants, it increases the mean chronological lifespans of mutants 
lacking other components of the outer (i.e., Mdm30p) or inner (i.e., Mgm1p and Pcp1p) 
membrane fusion machines. 
 
 
Figure 2.15. Hypothesis: LCA extends longevity of wild-type yeast by targeting Fzo1p 
and Ugo1p in the outer membranes of fusion partners. 
33  
2.3.2.   Discovering mechanisms that underlie the role of mitochondria in longevity 
regulation 
One of the objectives of studies described in this thesis was to establish the 
mechanism that links age-related changes in mitochondrial morphology to an apoptosis- 
like cell death of aging yeast. Based on findings described in previous section, we 
hypothesized that: (1) the observed fragmentation of the mitochondrial network in 
chronologically aging yeast cells that enter ST phase (Figures 2.4, 2.10 and 2.11) could 
trigger apoptosis; and (2) this age-related, mitochondria-controlled apoptosis could play 
an essential role in regulating longevity. In support of this hypothesis, we found that 
chronologically aging non-CR yeast cells die exhibiting characteristic markers of 
apoptosis (Figure 2.16) such as nuclear fragmentation (Figure 2.17), PS translocation 
from the inner to the outer leaflet of the plasma membrane (Figure 2.18), cleavage of 
chromosomal DNA (Figure 2.19), mitochondrial fragmentation (Figure 2.20) and the 
efflux of cytochrome c from mitochondria (Figures 2.21 and 2.22). We demonstrated that 
a CR diet - which slows down the fragmentation of the mitochondrial tubular network 
early in ST phase - delays such age-related apoptosis (Figures 2.17 to 2.22). Moreover, 
we also revealed that the anti-aging compound LCA - which under CR conditions 
completely abolishes mitochondrial fragmentation - prevents age-related apoptosis even 
in CR yeast that have reached late ST phase (Figures 2.17 to 2.22). 
It should be emphasized that, as we recently demonstrated, CR also significantly 
reduces the susceptibility of yeast to apoptosis induced in response to a short-term 
exposure to exogenous hydrogen peroxide or acetic acid, and LCA almost completely 











Figure 2.17. CR delays and LCA almost completely abolishes nuclear fragmentation, a 




Figure 2.18. CR delays and LCA almost completely abolishes externalization of PS, a 






Figure 2.19. CR delays and LCA almost completely abolishes cleavage of chromosomal 
 







Figure 2.20. CR delays and LCA almost completely abolishes mitochondrial 
fragmentation, a hallmark event of apoptosis. 
 
 
Figure 2.21. CR delays and LCA almost completely abolishes the efflux of cytochrome c 







Figure 2.22. CR delays and LCA almost completely abolishes the efflux of cytochrome c 




and acetic acid-induced forms of apoptosis have been linked to mitochondrial 
fragmentation, mitochondrial outer membrane permeabilization, and the release of 
several intermembrane space proteins from mitochondria [102, 104 - 109, 126]. 
Importantly, we found that the age-related apoptotic cell death of CR yeast during late ST 
 
phase depends on the metacaspase Yca1p as well as on such mitochondrial 
intermembrane space proteins as cytochrome c, Aif1p and Nuc1p. In fact, lack of Yca1p, 
both isoforms (i.e., Cyc1p and Cyc7p) of cytochrome c, Aif1p or Nuc1p extends 
longevity of chronologically aging yeast even under CR conditions (Figure 2.23). 
Furthermore, the pro-aging activities of at least some of these proteins could be reduced 
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by LCA, which under CR conditions increases the chronological lifespans of mutants that 
lack only one of them but maintain the others (Figures 2.24 to 2.27). Moreover, we found 
that LCA increases the chronological lifespans of mutants that lack Yca1p, both isoforms 
(i.e., Cyc1p and Cyc7p) of cytochrome c, Aif1p or Nuc1p to a significantly lesser degree 
than it does for wild-type strain (Figures 2.24 to 2.27). We therefore hypothesize that 
each of these pro-apoptotic proteins plays a dual role in regulating the beneficial effect of 
CR and LCA on yeast longevity. Specifically, while Yca1p, both isoforms (i.e., Cyc1p 
and Cyc7p) of cytochrome c, Aif1p and Nuc1p weaken (by a yet-to-be-established 
mechanism) the lifespan-expending effect of CR, these pro-apoptotic proteins somehow 
enhance the ability of LCA to extend yeast longevity under CR conditions (Figure 2.28). 
 
 
Figure 2.23. Age-related apoptosis of CR yeast during late ST phase depends on the 
metacaspase Yca1p and mitochondrial intermembrane space proteins cytochrome c (a 





Figure 2.24. LCA increases the chronological lifespan of a mutant that lacks the 
metacaspase Yca1p, but to a significantly lesser degree than it does for WT strain. Thus, 
paradoxically, Yca1p plays an essential role in promoting the anti-aging effect of LCA. 
 
 
Figure 2.25. LCA increases the chronological lifespan of a mutant that lacks the Cyc1p 
and Cyc7p isoforms of cytochrome c, but to a significantly lesser degree than it does for 
wild-type strain. Thus, paradoxically, cytochrome c plays an essential role in promoting 




Figure 2.26. LCA increases the chronological lifespan of a mutant strain that lacks the 
apoptosis inducing factor Aif1p, but to a significantly lesser degree than it does for wild- 
type strain. Thus, paradoxically, Aif1p plays an essential role in promoting the anti-aging 
effect of LCA. 
 
 
Figure 2.27. LCA increases the chronological lifespan of a mutant that lacks the pro- 
apoptotic endonuclease Nuc1p, but to a significantly lesser degree than it does for wild- 
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type strain. Thus, paradoxically, Nuc1p plays an essential role in promoting the anti- 









Figure 2.28. Dual roles for the pro-apoptotic proteins Yca1p, cytochrome c, Aif1p and 
 





It needs to be emphasized that, as we found, the ability of CR to delay 
mitochondrial fragmentation in early ST phase and attenuate both age-related and 
exogenously induced apoptosis coincides with its ability to slow down the release of 
cytochrome c from mitochondria into the cytosol (Figures 2.21 and 2.22). Moreover, we 
demonstrated that LCA - which under CR conditions impedes mitochondrial 
fragmentation late in ST phase and prevents both age-related and exogenously induced 
apoptosis - completely abolishes such efflux of cytochrome c from mitochondria (Figures 
2.21 and 2.22). Based on these findings, we hypothesize that the age-dependent dynamics 
of the mitochondrial tubular network regulates longevity by modulating age-related 
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apoptosis. This mitochondria-controlled apoptosis: (1) is triggered by the efflux of the 
pro-apoptotic proteins cytochrome c, Aif1p and Nuc1p from mitochondria in aging cells; 
and (2) depends on the metacaspase Yca1p. In our hypothesis, CR delays the 
fragmentation of the mitochondrial tubular network during early ST phase. This, in turn, 
slows down the age-related exit of pro-apoptotic proteins from mitochondria, attenuates 
apoptotic cell death, and ultimately prolongs lifespan. Moreover, we hypothesize that 
LCA further increases the lifespan of CR yeast by preventing mitochondrial 
fragmentation during late ST phase, thereby averting the age-related exit of pro-apoptotic 
proteins from mitochondria and inhibiting apoptosis. 
As we found, LCA extends yeast longevity in part by promoting the ability of 
Fzo1p and Ugo1p to fuse the opposing mitochondrial outer membranes, thereby 
preventing fragmentation of the mitochondrial network (see above in this chapter). It 
should be stressed that, by maintaining the connectivity of the mitochondrial network, 
mitochondrial fusion is known to play a key role in cell and organismal life and death 
[130 - 132]. Defects in mitochondrial fusion in humans are known to manifest primarily 
as neurodegenerative diseases [132]. In fact, mutations affecting mitochondrial fusion 
proteins Mfn2 (a mammalian homolog of yeast Fzo1p) and OPA1 (a mammalian 
homolog of yeast Mgm1p) have been shown to lead to peripheral neuropathy Charcot- 
Marie-Tooth type 2A and dominant optic atrophy 1, respectively [130 - 132]. One of the 
primary phenotypes associated with the impairment of mitochondrial fusion in patients 
suffering from these diseases is loss of mitochondrial respiratory function, which is an 
important factor contributing to their etiology [130 - 132]. It is therefore important to 
mention that recent unpublished findings of other students in the Titorenko laboratory 
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revealed that under CR conditions LCA is unable to extend the lifespans of mutants 
lacking components of the complexes III, IV and V of the mitochondrial electron 
transport chain (ETC) or mitochondrial chaperones required for the assembly of these 
complexes (Beach et al., manuscript in preparation). Thus, the ability of LCA to delay 
aging relies on the intact mitochondrial respiratory chain. Moreover, in studies described 
in this chapter of the thesis we found that LCA alters the age-dependent dynamics of 
several mitochondrial activities in CR yeast, including oxygen consumption, 
mitochondrial membrane potential (∆ψ) and ROS generation. In particular, in CR yeast 
entering D phase, LCA decreases the amplitude of the spike in all these mitochondrial 
activities (Figures 2.29 to 2.31). Furthermore, during PD and ST phases, LCA prevents a 
sharp decline of all these activities, maintaining them at the levels they reached by the 
end of PD phase (Figures 2.29 to 2.31). 
Interestingly, by analyzing yeast mutants lacking redundant components of the 
mitochondrial tricarboxylic acid (TCA) cycle, other students in the Titorenko laboratory 
recently revealed that the effects of LCA on lifespan and mitochondrial functions are 
very similar to those seen in CR yeast carrying mutations eliminating the Idh1p or Idh2p 
subunits of isocitrate dehydrogenase (Beach et al., manuscript in preparation). One could 
reason that mitochondria lacking a single redundant component of the TCA cycle (such 
as Idh1p or Idh2p) would still be able to produce NADH and FADH2, the two donors of 
electrons for the ETC, but in reduced amounts. This, in turn, would reduce mitochondrial 
 
ROS generated as by-products of electron flow through the ETC. As other students in the 
Titorenko laboratory demonstrated, akin to LCA (Figures 2.29 to 2.31), the idh1∆ and 
idh2∆ mutations extend the chronological lifespan of CR yeast and alter - in an LCA-like 
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fashion - the age-dependent dynamics of oxygen consumption, ∆ ψ and ROS generation. 
Specifically, it was revealed that, in CR yeast entering D phase, both mutations decrease 
the amplitude of the spike in all of these mitochondrial activities (Beach et al., manuscript 
in preparation). During PD and ST phases, both mutations were shown to prevent a sharp 
decline of all these activities. In addition, it was found that, during ST phase, idh1∆ and 
idh2∆ avert the loss of cytochrome c oxidase (CCO) and succinate dehydrogenase (SDH) 
activities (Beach et al., manuscript in preparation), both of which are known to represent 
the major mitochondrial targets of oxidative damage by ROS [133, 134]. Furthermore, it 
was demonstrated by other students in the Titorenko laboratory that both mutations 
protect aconitase (ACO), an enzyme of the TCA cycle, from age-related inactivation 
(Beach et al., manuscript in preparation) known to be caused by the oxidation-dependent 
loss of one iron from its Fe/S cluster [135]. Moreover, using mass spectrometry-based 
proteomics, other students in the Titorenko laboratory revealed that idh1∆ and idh2∆ 
increase the abundance of cytosolic and mitochondrial anti-stress chaperones, ROS- 
decomposing proteins, and proteins that protect mtDNA from oxidative damage (Beach 
et al., manuscript in preparation). Consistent with the elevated levels of these proteins, 
both mutations were found to enhance heat-shock and oxidative stress resistance of aging 
CR yeast. Importantly, it was shown that, akin to idh1∆ and idh2∆, LCA protects yeast 





Figure 2.29. LCA alters the age-dependent dynamics of cellular respiration by 


















Based on our observation that LCA alters the age-dependent dynamics of several 
mitochondrial activities in CR yeast, including oxygen consumption, mitochondrial 
membrane potential (∆ψ) and ROS generation and considering data of other students in 
the Titorenko laboratory on the effect of idh1∆ and idh2∆ on longevity and mitochondrial 
functions, we hypothesize that age-related, mitochondria-controlled apoptosis is not the 
only mechanism by which mitochondria regulate longevity. The other mechanism is 
based on the LCA-dependent ability of mitochondria in aging yeast to maintain ROS 
homeostasis. In particular, we propose that ROS, which are mostly generated as by- 
products of mitochondrial respiration [136, 137], play a dual role in regulating longevity 
(Figure 2.32). First, if yeast mitochondria are unable (due to a dietary regimen or 
unavailability of LCA) to maintain ROS concentration below a critically high level, ROS 
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promote aging by oxidatively damaging certain mitochondrial proteins (such as CCO, 
SDH and ACO) (Figure 2.32). Second, if yeast mitochondria can (due to a dietary 
regimen or availability of LCA) maintain ROS concentration at an “optimal” level, ROS 
delay aging (Figure 2.32). This “optimal” level of ROS is insufficient to damage cellular 
macromolecules but can activate certain signaling networks [133, 136 - 142] that extend 
lifespan by increasing the abundance or activity of stress-protecting and other anti-aging 
proteins. The term “mitohormesis” has been coined for such anti-aging role of 
mitochondrially produced ROS [143]; the term “hormesis” refers to a beneficial defence 




Figure 2.32. LCA extends longevity by reducing the damaging effect of ROS and 
 
amplifying their “hormetic” effect. 
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3 LCA extends longevity of chronologically aging yeast only if added at certain 






One way to look at the complexity of the aging process, in which a limited 
number of evolutionarily conserved nutrient- and energy-sensing signaling pathways 
(hereafter often called “master regulators”) orchestrate a plethora of cellular processes in 
space and time [1, 50, 146, 147], is to consider each of these numerous processes as a 
functional module integrated with other modules into a biomolecular network [148 - 
151]. In this conceptual framework (1) a synergistic action of individual modules 
comprising the network could define longevity by establishing the rate of cellular and 
organismal aging; and (2) the relative impact of each module on the rate of aging in a 
particular organism or cell type could differ at various stages of its lifetime and could 
also vary in different organisms and cell types [24, 148 - 152]. Initially developed for 
theoretical modeling of the complexity of the senescence process in mammalian 
organisms [153], a network biology approach has been intensively used in recent years 
for reconstructing biomolecular networks of longevity and aging on the cellular and 
organismal levels. Numerous models of such networks have been proposed based on 
system biological and computational analyses of protein-protein interactions, age-related 
changes in gene expression or longevity-defining metabolic alterations [24, 147, 154 - 
162]. Here we extend the network theory of aging by proposing that a biomolecular 
longevity network could progress through a series of checkpoints. At each of these 
checkpoints, a distinct set of master regulators senses the functional states of critical 
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modules comprising the network. Based on this information and considering the input of 
some environmental cues (such as caloric and dietary intake, environmental stresses, 
endocrine factors, etc.), master regulators modulate certain processes within monitored 
modules in order to limit the age-related accumulation of molecular and cellular damage. 
The resulting changes in the dynamics of individual modules comprising the network and 
in its general configuration are critically important for defining longevity by establishing 
the rate of cellular and organismal aging. 
A confirmation of this concept for a stepwise development of a longevity network 
configuration at a series of checkpoints, each being monitored by a limited set of 
checkpoint-specific master regulators, comes from studies that revealed distinctive timing 
requirements for modulating the pace of organismal aging in the nematode 
Caenorhabditis elegans. It seems that this organism employs at least three independent 
regulatory systems that, by monitoring a particular cellular process or processes during a 
specific stage of life, use this information to establish the rate of cellular and organismal 
aging. The first of these three regulatory systems influences lifespan by operating only 
during larval development [163, 164]. By monitoring mitochondrial respiration, 
electrochemical membrane potential and ATP production early in life, during the L3/L4 
larval stage, it establishes the rate of aging that persists during adulthood [163, 164]. 
Mechanisms underlying the essential role of this first regulatory system in defining 
longevity of C. elegans may involve (1) a remodeling of mitochondria-confined ATP 
production pathways during larval development, which may establish a specific 
configuration of the longevity-defining metabolic network in a cell-autonomous manner 
[165, 166] and (2) a retrograde signalling pathway that in response to mild mitochondrial 
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impairment and stress during the L3/L4 larval stage activates UBL-5 (ubiquitin-like 
protein 5)/DVE-1 (defective proventriculus protein 1)-driven expression of the 
mitochondria-specific unfolded protein response (UPRmt) genes in the nucleus, thereby 
stimulating synthesis of a subset of UPRmt proteins that can extend longevity not only 
 
cell-autonomously but also in a cell-non-autonomous fashion [167]. The second 
regulatory system operates exclusively during adulthood, mainly during early adulthood, 
to influence the lifespan of C. elegans via the insulin/IGF-1 (insulin-like growth factor 1) 
longevity signaling pathway and the transcription factor DAF-16 (dauer formation 
protein 16) [163, 168]. Noteworthy, the magnitude of the effect of this second regulatory 
system on lifespan declines with age and becomes insignificant after several days of 
adulthood [163]. The third regulatory system influences the lifespan of C. elegans in a 
diet-restriction-specific fashion by operating exclusively during adulthood [169]. This 
system regulates longevity via the transcription factor PHA-4 (pharynx development 
protein 4) only in response to reduced food intake. Importantly, the PHA-4-mediated 
regulatory system operates independently of the other two regulatory systems modulating 
the rate of aging in C. elegans [169]. In our hypothesis for a stepwise development of a 
longevity network configuration at a series of checkpoints, a genetic, dietary or 
pharmacological anti-aging intervention may modulate the key cellular process or 
processes that are monitored at a particular checkpoint by a master regulator of the 
longevity control system. In C. elegans, UBL-5/DVE-1, DAF-16 and PHA-4 may 
function as the checkpoint-specific master regulators of longevity by governing 
progression through the three consecutive checkpoints operating during larval 
development and early adulthood [163, 167 - 169]. 
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It seems that some general aspects of the proposed here hypothesis of the longevity 
control system progressing through a series of checkpoints could be applicable to 
laboratory mice and rats. In fact, although a CR diet considerably extends lifespan in 
these organisms even if it is implemented at the age at which skeletal development is 
complete, the maximal benefit of this low-calorie diet for longevity can be achieved only 
if CR is initiated during the rapid growth period [170 - 172]. These findings suggest that 
laboratory mice and rats (1) could employ a CR-dependent longevity control system that, 
by monitoring some key, longevity-defining cellular processes, can establish a particular 
rate of cellular and organismal aging; and (2) could have at least two checkpoints, one in 
early adulthood and another in late adulthood, at which the proposed CR-dependent 
longevity control system senses the rate and/or efficiency of the critical cellular processes 
that define longevity. It is conceivable therefore that the proposed CR-dependent 
longevity control system in laboratory mice and rats can extend longevity even if the rate 
and efficiency of the critical, CR-modulated cellular processes are appropriate only at the 
late-adulthood checkpoint, but not as markedly as if they are suitable already at the 
checkpoint in early adulthood. 
According to the proposed here hypothesis for a stepwise development of a 
longevity network configuration at a series of checkpoints, a pharmacological anti-aging 
intervention may modulate the key longevity-defining cellular processes that are 
monitored at a particular checkpoint by a master regulator of the longevity control 
system. Several anti-aging compounds are currently known for their ability to extend 
longevity across phyla and improve health by beneficially influencing age-related 
pathologies [1, 2, 14, 173]. Only one of these anti-aging compounds, a macrocyclic 
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lactone rapamycin synthesized by soil bacteria to inhibit growth of fungal competitors 
within an ecosystem [174], has been examined for its effects on lifespan and healthspan if 
implemented at different ages of an organism. If fed to genetically heterogeneous mice 
beginning at 270 days or 600 days of age, this specific inhibitor of the nutrient-sensory 
protein kinase mTORC1 (mammalian target of rapamycin complex 1) has been shown to 
be equally efficient in extending lifespan and beneficially influencing age-related 
pathologies [173, 175 - 178]. Our recent studies provided evidence that (1) LCA, a bile 
acid, extends longevity of chronologically aging yeast if added to growth medium at the 
time of cell inoculation [14]; and (2) longevity in chronologically aging yeast is 
programmed by the level of metabolic capacity and organelle organization that they 
developed, in a diet-specific fashion, before entering a quiescent state - and, thus, that 
chronological aging in yeast is likely to be the final step of a developmental program 
progressing through at least one checkpoint prior to entry into quiescence [24]. We 
therefore sought to investigate how LCA influences longevity and a compendium of 
longevity-defining cellular processes in chronologically aging yeast if added to growth 




3.2 Materials and Methods 
 
Strain and media 
 
 
The wild-type strain Saccharomyces cerevisiae BY4742 (MAT α his3∆1 leu2∆0 lys2∆0 
ura3∆0) was used in this study. Media components were as follows: (1) YEPD (0.2% 
glucose), 1% yeast extract, 2% peptone, 0.2% glucose; and (2) YEPD (2% glucose), 1% 





A plating assay for the analysis of chronological lifespan 
 
 
Cells were grown in YEPD (0.2% glucose) medium at 30oC with rotational shaking at 
 
200 rpm in Erlenmeyer flasks at a flask volume/medium volume ratio of 5:1. A sample of 
cells was removed from each culture at various time points. A fraction of the cell sample 
was diluted in order to determine the total number of cells per ml of culture using a 
hemacytometer. 10 μ l of serial dilutions (1:10 to 1:103) of cells were applied to the 
hemacytometer, where each large square is calibrated to hold 0.1 μ l. The number of cells 
in 4 large squares was then counted and an average was taken in order to ensure greater 
accuracy. The concentration of cells was calculated as follows: number of cells per large 
square x dilution factor x 10 x 1,000 = total number of cells per ml of culture. A second 
fraction of the cell sample was diluted and serial dilutions (1:102 to 1:105) of cells were 
 
plated onto YEPD (2% glucose) plates in triplicate in order to count the number of viable 
cells per ml of each culture. 100 μ l of diluted culture was plated onto each plate. After a 
48-h incubation at 30oC, the number of colonies per plate was counted. The number of 
 
colony forming units (CFU) equals to the number of viable cells in a sample. Therefore, 
the number of viable cells was calculated as follows: number of colonies x dilution factor 
x 10 = number of viable cells per ml. For each culture assayed, % viability of the cells 
was calculated as follows: number of viable cells per ml / total number of cells per ml x 
100%. The % viability of cells in mid-logarithmic phase was set at 100% viability for that 
particular culture. The life span curves for wild-type and some of the mutant strains were 
also validated using a LIVE/DEAD yeast viability kit (Invitrogen) following the 




Plating assays for the analysis of resistance to various stresses 
 
For the analysis of hydrogen peroxide resistance, serial dilutions (1:100 to 1:105) of wild- 
type and mutant cells removed from mid-logarithmic phase (day 1) and from diauxic 
phase (days 2 and 3) in YEPD (0.2% glucose) were spotted onto two sets of plates. One 
set of plates contained YEPD (2% glucose) medium alone, whereas the other set 
contained YEPD (2% glucose) medium supplemented with 5 mM hydrogen peroxide. 
Pictures were taken after a 3-day incubation at 30oC. 
For the analysis of oxidative stress resistance, serial dilutions (1:100 to 1:105) of 
 
wild-type and mutant cells removed from mid-logarithmic phase (day 1) and from 
diauxic phase (days 2 and 3) in YEPD (0.2% glucose) were spotted onto two sets of 
plates. One set of plates contained YEPD (2% glucose) medium alone, whereas the other 
set contained YEPD (2% glucose) medium supplemented with 2.5 mM of the 
superoxide/hydrogen peroxide-generating agent paraquat. Pictures were taken after a 3- 
day incubation at 30oC. 
For the analysis of heat-shock resistance, serial dilutions (1:100 to 1:105) of wild- 
 
type and mutant cells removed from mid-logarithmic phase (day 1) and from diauxic 
phase (days 2 and 3) in YEPD (0.2% glucose) were spotted onto two sets of YEPD (2% 
glucose) plates. One set of plates was incubated at 30oC. The other set of plates was 
initially incubated at 55oC for 30 min, and was then transferred to 30oC. Pictures were 
 
taken after a 3-day incubation at 30oC. 
 
For the analysis of salt stress resistance, serial dilutions (1:100 to 1:105) of wild- 
type and mutant cells removed from mid-logarithmic phase (day 1) and from diauxic 
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phase (days 2 and 3) in YEPD (0.2% glucose) were spotted onto two sets of plates. One 
set of plates contained YEPD (2% glucose) medium alone, whereas the other set 
contained YEPD (2% glucose) medium supplemented with 0.5 M NaCl. Pictures were 
taken after a 3-day incubation at 30oC. For the analysis of osmotic stress resistance, serial 
dilutions (1:100 to 1:105) of wild-type and mutant cells removed from mid-logarithmic 
 
phase (day 1) and from diauxic phase (days 2 and 3) in YEPD (0.2% glucose) were 
spotted onto two sets of plates. One set of plates contained YEPD (2% glucose) medium 
alone, whereas the other set contained YEPD (2% glucose) medium supplemented with 1 





Pharmacological manipulation of chronological lifespan 
 
Chronological lifespan analysis was performed as described above in this section. The 
lithocholic (LCA) [#L6250] bile acid was from Sigma. The stock solution of LCA in 
DMSO was made on the day of adding this compound to cell cultures. LCA was added to 
growth medium at the final concentration of 50 µM immediately following cell 
inoculation into the medium or on days 1, 2, 3, 5, 7, 9, 11 or 14 of cell culturing in the 
medium, as indicated. The final concentration of DMSO in yeast cultures supplemented 
with LCA (and in the corresponding control cultures supplemented with drug vehicle) 





Cell viability assay for monitoring the susceptibility of yeast to an apoptotic mode of 
cell death induced by hydrogen peroxide 
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A sample of cells was taken from a culture at a certain time-point. A fraction of the 
sample was diluted in order to determine the total number of cells using a 
hemacytometer. 2 × 107 cells were harvested by centrifugation for 1 min at 21,000 × g at 
room temperature and resuspended in 2 ml of YP medium containing 0.2% glucose as 
carbon source. Each cell suspension was divided into 2 equal aliquots. One aliquot was 
supplemented with hydrogen peroxide (#H325-500; Fisher Scientific) to the final 
concentration of 2.5 mM, whereas other aliquot remained untreated. Both aliquots were 
then incubated for 2 h at 30oC on a Labquake rotator (#400110; Thermolyne/Barnstead 
International) set for 360o rotation. Serial dilutions of cells were plated in duplicate onto 
 
plates containing YP medium with 2% glucose as carbon source. After 2 d of incubation 
 
at 30oC, the number of colony forming units (CFU) per plate was counted. The number of 
CFU was defined as the number of viable cells in a sample. For each aliquot of cells 
exposed to hydrogen peroxide, the % of viable cells was calculated as follows: (number 
of viable cells per ml in the aliquot exposed to hydrogen peroxide/number of viable cells 




Cell viability assay for monitoring the susceptibility of yeast to a necrotic mode of 
cell death induced by palmitoleic acid 
A sample of cells was taken from a culture at a certain time-point. A fraction of the 
sample was diluted in order to determine the total number of cells using a 
hemacytometer. 2 × 107 cells were harvested by centrifugation for 1 min at 21,000 × g at 
room temperature and resuspended in 2 ml of YP medium containing 0.2% glucose as 
carbon source. Each cell suspension was divided into 2 equal aliquots. One aliquot was 
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supplemented with palmitoleic acid (#P9417; Sigma) from a 50 mM stock solution (in 
 
10% chloroform, 45% hexane and 45% ethanol) [#650498, #248878 and #34852, 
respectively; all from Sigma]; the final concentration of palmitoleic acid was 0.15 mM 
(in 0.03% chloroform, 0.135% hexane and 0.135% ethanol). Other aliquot was 
supplemented with chloroform, hexane and ethanol added to the final concentrations of 
0.03%, 0.135% and 0.135%, respectively. Both aliquots were then incubated for 2 h at 
 
30oC on a Labquake rotator set for 360o rotation. Serial dilutions of cells were plated in 
duplicate onto plates containing YP medium with 2% glucose as carbon source. After 2 d 
of incubation at 30oC, the number of colony forming units (CFU) per plate was counted. 
The number of CFU was defined as the number of viable cells in a sample. For each 
aliquot of cells exposed to palmitoleic acid, the % of viable cells was calculated as 
follows: (number of viable cells per ml in the aliquot exposed to palmitoleic acid/number 






Measurement of the frequency of nuclear mutations 
 
The frequency of spontaneous point mutations in the CAN1 gene of nuclear DNA was 
evaluated by measuring the frequency of mutations that caused resistance to the antibiotic 
canavanine.10 A sample of cells was removed from each culture at various time-points. 
Cells were plated in triplicate onto YNB (0.67% Yeast Nitrogen Base without amino 
acids [#DF0919153; Fisher Scientific]) plates containing 2% glucose and supplemented 
with L-canavanine (50 mg/L), histidine, leucine, lysine and uracil (#C1625, #H8125, 
#L8912, #L5751 and #U0750, respectively; all from Sigma). In addition, serial dilutions 
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of each sample were plated in triplicate onto YP plates containing 2% glucose for 
measuring the number of viable cells. The number of CFU was counted after 4 d of 
incubation at 30oC. For each culture, the frequency of mutations that caused resistance to 
canavanine was calculated as follows: number of CFU per ml on YNB plates containing 
2% glucose, L-canavanine (50 mg/L), histidine, leucine, lysine and uracil/number of CFU 
 





Measurement of the frequency of mitochondrial mutations affecting mitochondrial 
components 
The frequency of spontaneous single-gene (mit- and syn-) and deletion (rho- and rhoo) 
 
mutations in mtDNA affecting essential mitochondrial components was evaluated by 
measuring the fraction of respiratory-competent (rho+) yeast cells remaining in their 
aging population. rho+ cells maintained intact their mtDNA and their nuclear genes 
encoding essential mitochondrial components. Therefore, rho+ cells were able to grow on 
glycerol, a non-fermentable carbon source. In contrast, mutant cells deficient in 
mitochondrial respiration were unable to grow on glycerol. These mutant cells carried 
mutations in mtDNA (including single-gene mit- and syn- mutations or large deletions 
rho-) or completely lacked this DNA (rhoo mutants).10 Serial dilutions of cell samples 
 
removed from different phases of growth were plated in triplicate onto YP plates 
containing either 2% glucose or 3% glycerol (#BP229-4; Fisher Scientific) as carbon 
source. Plates were incubated at 30oC. The number of CFU on YP plates containing 2% 
glucose was counted after 2 d of incubation, whereas the number of CFU on YP plates 
containing 3% glycerol was counted after 6 d of incubation. For each culture, the 
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percentage of respiratory-deficient (mit-, syn-, rho-, rhoo and pet-) cells was calculated as 
follows: 100 - [(number of CFU per ml on YP plates containing 3% glycerol/number of 
CFU per ml on YP plates containing 2% glucose) × 100]. 
The frequency of spontaneous point mutations in the rib2 and rib3 loci of mtDNA 
was evaluated by measuring the frequency of mtDNA mutations that caused resistance to 
the antibiotic erythromycin.10 These mutations impair only mtDNA.10 A sample of cells 
was removed from each culture at various time-points. Cells were plated in triplicate onto 
YP plates containing 3% glycerol and erythromycin (1 mg/ml) [#227330050; Acros 
Organics]. In addition, serial dilutions of each sample were plated in triplicate onto YP 
plates containing 3% glycerol as carbon source for measuring the number of respiratory- 
competent (rho+) cells. The number of CFU was counted after 6 d of incubation at 30oC. 
For each culture, the frequency of mutations that caused resistance to erythromycin was 
calculated as follows: number of CFU per ml on YP plates containing 3% glycerol and 






Statistical analysis was performed using Microsoft Excel’s (2010) Analysis ToolPack- 
VBA. All data are presented as mean ± SEM. The p values were calculated using an 
unpaired two-tailed t test. 
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3.3       Results 
 
3.3.1 LCA increases the chronological lifespan of yeast cultured under CR or non- 
CR conditions only if added at certain critical periods 
We sought to examine if the addition of LCA to chronologically aging yeast at 
different periods of lifespan has an effect on the longevity-extending efficacy of this bile 
acid. Yeast cells were cultured in YP medium under CR conditions on 0.2% glucose or 
under non-CR conditions on 2% glucose, and LCA was added to a cell culture 
immediately following cell inoculation into the medium (on day 0) or on day 1, 2, 3, 5, 7, 
9, 11 or 14 of cell culturing in this medium. LCA was used at the final concentration of 
 
50 µM, at which this natural anti-aging compound has been shown to exhibit the greatest 
beneficial effect on longevity of chronologically aging yeast under both CR and non-CR 
conditions [14]. 
We found that in yeast cultured under CR conditions on 0.2% glucose, there are 
two critical periods when the addition of LCA to growth medium can increase both their 
mean and maximum chronological lifespans (Figures 3.1 and 3.3). One of these two 
critical periods, which we term period 1, includes L (logarithmic) and D (diauxic) growth 
phases. The other critical period, which is called period 3, exists in early ST (stationary) 
phase. In contrast, LCA did not cause a significant extension of the mean or maximum 
chronological lifespan of CR yeast if it was added at period 2 or 4 that exists in PD (post- 





Figure 3.1. In yeast cultured under CR conditions on 0.2% glucose, there are two critical 
periods when the addition of LCA to growth medium can extend longevity. Wild-type 
yeast cells were cultured in YP medium initially containing 0.2% glucose, and LCA was 
added at the final concentration of 50 µM to a cell culture immediately following cell 
inoculation into the medium (on day 0) or on day 1, 2, 3, 5, 7, 9, 11 or 14 of cell culturing 
in this medium. The final concentration of DMSO in yeast cultures supplemented with 
LCA (and in the corresponding control cultures supplemented with compound vehicle) 
was 1% (v/v). Chronological lifespan analysis was performed as described in “Materials 
and Methods”. Data are presented as mean ± SEM (n = 8-12). Abbreviations: diauxic 





Figure 3.2. In yeast cultured under non-CR conditions on 2% glucose, there is only one 
critical period when the addition of LCA to growth medium can extend longevity. Wild- 
type yeast cells were cultured in YP medium initially containing 2% glucose, and LCA 
was added at the final concentration of 50 µM to a cell culture immediately following cell 
inoculation into the medium (on day 0) or on day 1, 2, 3, 5, 7, 9, 11 or 14 of cell culturing 
in this medium. The final concentration of DMSO in yeast cultures supplemented with 
LCA (and in the corresponding control cultures supplemented with compound vehicle) 
was 1% (v/v). Chronological lifespan analysis was performed as described in “Materials 




Figure 3.3. In yeast cultured under CR conditions on 0.2% glucose, there are two critical 
periods when the addition of LCA to growth medium can extend longevity. In yeast 
cultivated under non-CR conditions on 2% glucose, there is only one such a period. The 
mean (A) and maximum (B) chronological lifespans of different wild-type yeast cultures 
are shown. Wild-type yeast cells were cultured under CR or non-CR conditions and LCA 
was added as described in the legends for Fig. 1 and 2, respectively. Chronological 
lifespan analysis was performed as described in “Materials and Methods”. Data are 
presented as mean ± SEM (n = 8-12 for (A); n = 6-7 for (B)); *p < 0.05 (relative to the 
mean or maximum chronological lifespan of yeast not exposed to LCA). 
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We also found that in yeast cultivated under non-CR conditions on 2% glucose, 
there is only one critical period, during L and D phases, when the addition of LCA to 
growth medium can increase both their mean and maximum chronological lifespans 
(Figures 3.2 and 3.3). However, if LCA was added to non-CR yeast at any time-point 
after this critical period ended, it did not significantly alter their mean or maximum 
chronological lifespan (Figures 3.2 and 3.3). Thus, unlike a substantial beneficial effect 
of LCA on yeast longevity seen if it was added in early ST phase under CR conditions, 
this bile acid was unable to extend longevity of chronologically aging yeast under non- 




3.3.2 There are several ways through which LCA could differentially influence 
longevity if added to CR yeast at different periods of their lifespan 
Aging of multicellular and unicellular eukaryotic organisms affects numerous 
longevity-defining processes within cells [1, 2, 49, 50, 146, 147]. It is conceivable 
therefore that the observed ability of LCA to extend longevity of chronologically aging 
yeast under CR conditions only if added at period 1 or 3 of their lifespan (Figures 3.1 and 
3.3) could be due to its differential and, perhaps, enduring effects on certain longevity- 
extending and longevity-shortening processes controlled at different lifespan periods. 
One could envisage several ways through which LCA can differentially influence these 
longevity-defining processes following its addition at different periods of yeast 
chronological lifespan (Figure 3.4). For example, LCA could activate a longevity- 
extending process (or several processes) controlled at certain checkpoints that may exist 




Figure 3.4. There are several ways through which LCA could differentially influence 
some longevity-extending and longevity-shortening processes following its addition at 
different periods of yeast chronological lifespan. LCA could control these longevity- 
defining processes at certain checkpoints that may exist in L/D and early ST phases 





longevity-shortening processes at these envisioned lifespan checkpoints or having an 
effect on any longevity-defining processes during periods 2 and 4 in PD and late ST 
phases (Figure 3.4; see the 1st way). Alternatively, LCA could inhibit a longevity- 
shortening process (or several processes) controlled at certain checkpoints that may exist 
in L/D and early ST phases (periods 1 and 3, respectively), without influencing 
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longevity-extending processes at these envisioned lifespan checkpoints or having an 
effect on any longevity-defining processes during periods 2 and 4 in PD and late ST 
phases (Figure 3.4; see the 2nd way). Moreover, the observed ability of LCA to extend 
longevity of chronologically aging yeast under CR conditions only if added at periods 1 
and 3 of their lifespan could be also due to various combinations of the 1st and the 2nd 
ways outlined above (Figure 3.4; see other ways). We therefore sought to examine how 
the addition of LCA at different periods of chronological lifespan in yeast cultured under 
CR conditions influences longevity-extending and longevity-shortening processes 




3.3.3 LCA makes yeast cells resistant to mitochondria-controlled apoptotic death, 
a longevity-shortening process, only if added at period 1, 2 or 3 of their 
chronological lifespan 
A short-term exposure of yeast to hydrogen peroxide, acetic acid, hyperosmotic 
stress, α pheromone or several other exogenous agents causes apoptotic cell death that 
has been linked to mitochondrial fragmentation, mitochondrial outer membrane 
permeabilization and the release of several intermembrane space proteins from 
mitochondria [103, 105, 109, 179]. The exit of Aif1p (apoptosis inducing factor 1) and 
Nuc1p (endonuclease G) from yeast mitochondria and their subsequent import into the 
nucleus trigger such exogenously induced apoptosis by promoting DNA cleavage [104, 
107]. Another intermembrane space protein that is released from yeast mitochondria 
during exogenously induced apoptosis is cytochrome c [102, 105, 109]. Akin to its 
essential role in triggering the apoptotic caspase cascade in mammalian cells [98], 
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cytochrome c in the cytosol of yeast cells activates the metacaspase Yca1p [105, 111, 
 
112, 180]. Importantly, chronologically aging yeast cells die, in an Aif1p-, Nuc1p- and 
Yca1p-dependent fashion, exhibiting characteristic markers of apoptosis such as 
chromatin condensation, nuclear fragmentation, DNA cleavage, PS externalization, ROS 
production and caspase activation [104, 107, 114 - 117]. Thus, the chronological aging of 
yeast is linked to an apoptosis-like, mitochondria-controlled programmed cell death [118 
- 121, 181]. It should be emphasized that mutations eliminating pro-apoptotic proteins as 
well as such potent anti-aging interventions as a CR diet and LCA (1) extend longevity of 
chronologically aging yeast; (2) delay age-related apoptotic death controlled by 
mitochondria; and (3) reduce the susceptibility of yeast to cell death triggered by a short- 
term exposure to exogenous hydrogen peroxide and known to be caused by 
mitochondria-controlled apoptosis [14, 24, 99, 104, 107, 109, 114 - 121, 126, 181]. Taken 
together, these findings strongly support the notion that mitochondria-controlled 
apoptotic death plays an essential role in regulating longevity of chronologically aging 
yeast. This form of longevity-defining cell death can be triggered by a brief exposure of 
yeast to exogenous hydrogen peroxide [14, 24, 99, 109, 126]. We therefore examined 
how the addition of LCA at different periods of chronological lifespan influences a 
longevity-shortening process of mitochondria-controlled apoptotic cell death in yeast 
cultured under CR on 0.2% glucose. We monitored the susceptibility of yeast to cell 
death triggered by a short-term (for 2 h) exposure to exogenous hydrogen peroxide 
known to cause mitochondria-controlled apoptosis. We found that if added to growth 
medium on day 0, 1, 2, 3, 5, 7, 9 or 11, LCA reduces the susceptibility of CR yeast to 
apoptosis induced by a brief exposure to exogenous hydrogen peroxide following LCA 
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addition; this effect of LCA persists through the rest of the lifespan (Figure 3.5). In 
contrast, if added to growth medium on day 14, LCA does not alter the susceptibility of 
CR yeast to this form of apoptotic cell death for the remainder of the lifespan (Figure 
3.5). Thus, LCA makes yeast cells resistant to mitochondria-controlled apoptotic death, a 
longevity-shortening process, only if added at period 1, 2 or 3 of chronological lifespan. 
This effect of LCA persists long after each of these lifespan periods ended. 
 
 
Figure 3.5. LCA reduces the susceptibility of yeast cells to mitochondria-controlled 
apoptotic death, a longevity-shortening process, only if added at period 1, 2 or 3 of 
chronological lifespan and for the rest of the lifespan. Wild-type yeast cells were cultured 
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in YP medium initially containing 0.2% glucose, and LCA was added at the final 
concentration of 50 µM to a cell culture immediately following cell inoculation into the 
medium (on day 0) or on day 1, 2, 3, 5, 7, 9, 11 or 14 of cell culturing in this medium. 
The final concentration of DMSO in yeast cultures supplemented with LCA (and in the 
corresponding control cultures supplemented with compound vehicle) was 1% (v/v). Cell 
viability assay for monitoring the susceptibility of yeast to an apoptotic mode of cell 
death induced by a 2-h exposure to exogenous hydrogen peroxide was performed as 
 
described in “Materials and Methods”. Data are presented as mean ± SEM (n = 3 - 5); *p 
 





3.3.4 LCA differentially influences the susceptibility of chronologically aging yeast 
to palmitoleic acid-induced necrotic cell death, a longevity-shortening 
process, if added at different periods of their lifespan 
In our recently proposed model for a mechanism linking yeast longevity and lipid 
dynamics in the endoplasmic reticulum, lipid bodies and peroxisomes, a remodeling of 
lipid metabolism in chronologically aging non-CR yeast shortens their lifespan by 
causing premature death in part due to necrotic cell death triggered by the accumulation 
of free fatty acids [14, 24, 81, 91, 182]. Importantly, both CR and LCA not only extend 
longevity of chronologically aging yeast but also reduce their susceptibility to a form of 
necrotic cell death triggered by a short-term exposure to exogenous palmitoleic fatty acid 
[14, 24, 81, 91, 182]. These findings imply that palmitoleic acid-induced necrotic cell 
death plays an essential role in regulating longevity of chronologically aging yeast. We 
therefore assessed how the addition of LCA at different periods of chronological lifespan 
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influences a longevity-shortening process of necrotic cell death in yeast cultured under 
CR on 0.2% glucose. We examined the susceptibility of yeast to cell death triggered by a 
short-term (for 2 h) exposure to exogenous palmitoleic acid. We found that if added to 
growth medium on day 0, 1 or 2, LCA reduces the susceptibility of CR yeast to necrosis 
induced by a brief exposure to palmitoleic acid following LCA addition; this effect of 
LCA persists through the remainder of the lifespan (Figure 3.6). In contrast, LCA either 
does not influence (if added on day 3, 9, 11 or 14) or increases for the rest of the lifespan 
(if added on day 5 or 7) the susceptibility of CR yeast to this form of necrotic cell death 
(Figure 3.6). 
Thus, LCA makes yeast cells resistant to palmitoleic acid-induced necrotic death, a 
longevity-shortening process, only if added at period 1 that includes L and D growth 
phases; this effect of LCA persists long after the end of period 1.  It is conceivable that 
the observed inability of LCA to extend yeast longevity if added at period 2 of 
chronological lifespan (Figures 3.1 and 3.3) could be due to the observed stimulating 
lifelong effect of LCA on a palmitoleic acid-induced form of necrotic cell death if added 
at this period in PD phase (Figure 3.6). Furthermore, despite LCA extends longevity of 
chronologically aging yeast if added at period 3, it does not affect their susceptibility to 
necrotic cell death if added at this period in early ST phase (Figure 3.6). Moreover, the 
observed lack of an effect of LCA on yeast longevity if added at period 4 of 
chronological lifespan (Figures 3.1, 3.3 and 3.4) coincides with its inability to alter cell 




Figure 3.6. LCA differentially influences the susceptibility of chronologically aging 
yeast to palmitoleic acid-induced necrotic cell death, a longevity-shortening process, if 
added at different periods of lifespan. Wild-type yeast cells were cultured in YP medium 
initially containing 0.2% glucose, and LCA was added at the final concentration of 50 
µM to a cell culture immediately following cell inoculation into the medium (on day 0) or 
on day 1, 2, 3, 5, 7, 9, 11 or 14 of cell culturing in this medium. The final concentration 
of DMSO in yeast cultures supplemented with LCA (and in the corresponding control 
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cultures supplemented with compound vehicle) was 1% (v/v). Cell viability assay for 
monitoring the susceptibility of yeast to a necrotic mode of cell death induced by a 2-h 
exposure to exogenous palmitoleic acid was performed as described in “Materials and 
Methods”. Data are presented as mean ± SEM (n = 4); *p < 0.05 (relative to the % of 




3.3.5 LCA differentially influences a longevity-extending process of the 
maintenance of nuclear and mitochondrial genomes if added at different 
periods of yeast chronological lifespan 
A body of evidence supports the view that the maintenance of nDNA (nuclear 
DNA) and mtDNA (mitochondrial DNA) integrity is an essential longevity-extending 
process in evolutionarily distant organisms, including yeast [14, 24, 34, 49, 183, 184]. 
We therefore examined how the addition of LCA to yeast cultured under CR on 0.2% 
glucose at different periods of chronological lifespan influences (1) the frequency of 
spontaneous point mutations in the CAN1 gene of nDNA; (2) the frequencies of 
spontaneous single-gene (mit- and syn-) and deletion (rho- and rhoo) mutations in 
 
mtDNA, all causing a deficiency in mitochondrial respiration and impairing growth on 
glycerol; and (3) the frequencies of spontaneous point mutations in the rib2 and rib3 loci 
of mtDNA. 
We found that if added to growth medium on day 0, 1 or 2, LCA reduces the 
frequency of spontaneous point mutations in the CAN1 gene of nDNA for the rest of the 
lifespan (Figure 3.7). In contrast, LCA either does not influence (if added on day 3, 9, 11 
or 14) or increases for the remainder of the lifespan (if added on day 5 or 7) the frequency 
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of these spontaneous point mutations in nDNA (Figure 3.7). Thus, LCA stimulates the 
maintenance of nDNA integrity, an essential longevity-extending process, only if added 
at period 1 that includes L and D growth phases; this effect of LCA persists long after the 
end of period 1. Our findings also suggest that the observed lifelong inhibitory effect of 
LCA on the maintenance of nDNA integrity if it is added at period 2 of yeast 
chronological lifespan (Figure 3.7) could in part be responsible for the inability of LCA 
to extend yeast longevity if added at this period in PD phase (Figures 3.1, 3.3 and 3.4). 
Furthermore, despite LCA extends longevity of chronologically aging yeast if added at 
period 3, it does not influence the maintenance of nDNA integrity if added at this period 
during early ST phase (Figure 3.7). Moreover, the observed lack of an effect of LCA on 
yeast longevity if added at period 4 of chronological lifespan (Figures 3.1, 3.3 and 3.4) 
coincides with the inability of this compound to alter the efficacy of the maintenance of 
nDNA integrity if added at this period in late ST phase (Figure 3.7). 
We also found that if added to growth medium on day 0, 1, 2, 3, 5, 7, 9 or 11, LCA 
reduces for the rest of the lifespan (1) the frequencies of spontaneous single-gene (mit- 
and syn-) and deletion (rho- and rhoo) mutations in mtDNA, all causing a deficiency in 
mitochondrial respiration and impairing growth on glycerol (Figure 3.8); and (2) the 
frequencies of spontaneous point mutations in the rib2 and rib3 loci of mtDNA (Figure 
 
3.9). In contrast, if added to growth medium on day 14, LCA does not affect the 
frequencies of these spontaneous mutations in mtDNA (Figures 3.8 and 3.9). Thus, LCA 
stimulates the maintenance of mtDNA integrity, an essential longevity-extending process, 
only if added at period 1, 2 or 3 that exists in L/D, PD or early ST phase (respectively); 
this effect of LCA persists long after the end of each of these lifespan periods. Moreover, 
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the observed lack of an effect of LCA on yeast longevity if added at period 4 of 
chronological lifespan (Figures 3.1, 3.3 and 3.4) coincides with the inability of this 
compound to alter the efficacy of the maintenance of mtDNA integrity if added at this 
period in late ST phase (Figures 3.8 and 3.9). 
 
 
Figure 3.7. LCA differentially influences the maintenance of nDNA integrity, an 
essential longevity-extending process, if added at different periods of yeast lifespan. 
Wild-type yeast cells were cultured in YP medium initially containing 0.2% glucose, and 
LCA was added at the final concentration of 50 µM to a cell culture immediately 
following cell inoculation into the medium (on day 0) or on day 1, 2, 3, 5, 7, 9, 11 or 14 
of cell culturing in this medium. The final concentration of DMSO in yeast cultures 
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supplemented with LCA (and in the corresponding control cultures supplemented with 
compound vehicle) was 1% (v/v). The frequency of spontaneous point mutations in the 
CAN1 gene of nDNA was measured as described in “Materials and Methods”. Data are 
presented as mean ± SEM (n = 3); *p < 0.05 (relative to the frequency of spontaneous 
point mutations in the CAN1 gene of nDNA in yeast cultures not exposed to LCA). 
 
 
Figure 3.8. LCA differentially influences the maintenance of mtDNA integrity, an 
essential longevity-extending process, if added at different periods of yeast lifespan. 
Wild-type yeast cells were cultured in YP medium initially containing 0.2% glucose, and 
LCA was added at the final concentration of 50 µM to a cell culture immediately 
following cell inoculation into the medium (on day 0) or on day 1, 2, 3, 5, 7, 9, 11 or 14 
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of cell culturing in this medium. The final concentration of DMSO in yeast cultures 
supplemented with LCA (and in the corresponding control cultures supplemented with 
compound vehicle) was 1% (v/v). The frequencies of spontaneous single-gene (mit- and 
syn-) and deletion (rho- and rhoo) mutations in mtDNA, all causing a deficiency in 
 
mitochondrial respiration and impairing growth on glycerol, were measured as described 
in “Materials and Methods”. Data are presented as mean ± SEM (n = 5-6); *p < 0.05 
(relative to the frequencies of spontaneous mit-, syn-, rho- and rhoo mutations in mtDNA 
in yeast cultures not exposed to LCA). 
 
 
Figure 3.9. LCA differentially influences the maintenance of mtDNA integrity, an 
essential longevity-extending process, if added at different periods of yeast lifespan. 
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Wild-type yeast cells were cultured in YP medium initially containing 0.2% glucose, and 
LCA was added at the final concentration of 50 µM to a cell culture immediately 
following cell inoculation into the medium (on day 0) or on day 1, 2, 3, 5, 7, 9, 11 or 14 
of cell culturing in this medium. The final concentration of DMSO in yeast cultures 
supplemented with LCA (and in the corresponding control cultures supplemented with 
compound vehicle) was 1% (v/v). The frequencies of spontaneous point mutations in the 
rib2 and rib3 loci of mtDNA were measured as described in “Materials and Methods”. 
Data are presented as mean ± SEM (n = 3-4); *p < 0.05 (relative to the frequencies of 




3.3.6 LCA differentially influences a longevity-extending process of the 
development of resistance to chronic stresses if added at different periods of 
yeast chronological lifespan 
It is well established that the development of resistance to chronic (long-term) 
oxidative, thermal and osmotic stresses is an essential longevity-extending process in 
evolutionarily distant organisms, including yeast [1 - 3, 14, 24, 49, 53, 136, 137, 142, 
185]. We therefore examined how the addition of LCA to yeast cultured under CR on 
 
0.2% glucose at different periods of chronological lifespan influences their resistance to 
each of these chronic stresses. We found that if added to growth medium on day 0, 1, 2 or 
3, LCA increases for the remainder of the lifespan the resistance of yeast to chronic 
oxidative and thermal stresses, but does not alter cell susceptibility to chronic osmotic 
stress (Figures 3.10 to 3.16). Moreover, LCA increases the resistance of yeast to all three 
chronic stresses if added to growth medium on day 7, 9 or 11; this effect of LCA persists 
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long after its addition (Figures 3.10 to 3.16). In contrast, LCA does not alter cell 
susceptibility to any of these chronic stresses if added on day 5 or 14 (Figures 3.10 to 
3.16). Thus, in chronologically aging yeast LCA stimulates a longevity-extending process 
of the development of lifelong resistance to chronic oxidative and thermal stresses if 
added at period 1 that exists in L and D phases. If added at period 3 (which includes early 
ST phase), LCA not only stimulates the development of resistance to chronic oxidative 
and thermal stresses for the rest of the lifespan but also enhances a longevity-extending 
process of developing enduring resistance to chronic osmotic stress. If added at any of 
these two periods, LCA can extend longevity (Figures 3.1, 3.3 and 3.4). Noteworthy, the 
observed lack of an effect of LCA on yeast longevity if added at period 2 or period 4 of 
chronological lifespan (Figures 3.1, 3.3 and 3.4) coincides with the inability of this 
compound to alter cell susceptibility to any of these stresses at these two periods in PD 






In sum, this study provides evidence that LCA, a bile acid, can extend longevity 
 
of CR yeast only if added at period 1 (which includes L and D growth phases) or period 3 
(which exists in early ST phase) of chronological lifespan (Figure 49). In contrast, LCA 
is unable to extend the mean or maximum chronological lifespan of yeast cultured under 
CR conditions if added at period 2 or 4 in PD or late ST phase, respectively (Figure 49). 
We also found that longevity of yeast cultivated under non-CR conditions can be 
extended by LCA only if it is added at period 1, but not following its addition at period 2, 
 







Figure 3.10. Effect of LCA added at different periods of yeast chronological lifespan on 
cell growth under non-stressful conditions. Wild-type yeast cells were cultured in YP 
medium initially containing 0.2% glucose, and LCA was added at the final concentration 
of 50 µM to a cell culture immediately following cell inoculation into the medium (on 
day 0) or on day 1, 2, 3, 5, 7, 9, 11 or 14 of cell culturing in this medium. Spot assays 
were performed as described in “Materials and Methods”. Serial ten-fold dilutions of 
cells were spotted on plates with solid YP medium containing 2% glucose as carbon 





Figure 3.11. Effect of LCA added at different periods of chronological lifespan on the 
ability of yeast to resist chronic oxidative stress. Wild-type yeast cells were cultured in 
YP medium initially containing 0.2% glucose, and LCA was added at the final 
concentration of 50 µM to a cell culture immediately following cell inoculation into the 
medium (on day 0) or on day 1, 2, 3, 5, 7, 9, 11 or 14 of cell culturing in this medium. 
The final concentration of DMSO in yeast cultures supplemented with LCA (and in the 
corresponding control cultures supplemented with compound vehicle) was 1% (v/v). Spot 
assays for monitoring oxidative stress resistance were performed as described in 
“Materials and Methods”. Serial ten-fold dilutions of cells were spotted on plates with 
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solid YP medium containing 2% glucose as carbon source and 5 mM hydrogen peroxide. 







Figure 3.12. LCA differentially influences a longevity-extending process of the 
development of resistance to chronic oxidative stress if added at different periods of yeast 
chronological lifespan. A graphic presentation of the results of spot assays for monitoring 





Figure 3.13. Effect of LCA added at different periods of chronological lifespan on the 
ability of yeast to resist chronic thermal stress. Wild-type yeast cells were cultured in YP 
medium initially containing 0.2% glucose, and LCA was added at the final concentration 
of 50 µM to a cell culture immediately following cell inoculation into the medium (on 
day 0) or on day 1, 2, 3, 5, 7, 9, 11 or 14 of cell culturing in this medium. The final 
concentration of DMSO in yeast cultures supplemented with LCA (and in the 
corresponding control cultures supplemented with compound vehicle) was 1% (v/v). Spot 
assays for monitoring thermal stress resistance were performed as described in “Materials 
and Methods”. Serial ten-fold dilutions of cells were spotted on plates with solid YP 
medium containing 2% glucose as carbon source. Plates were initially incubated at 55oC 
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for 30 min, and were then transferred to 30oC. All pictures were taken after a 3-day 









Figure 3.14. LCA differentially influences a longevity-extending process of the 
development of resistance to chronic thermal stress if added at different periods of yeast 
chronological lifespan. A graphic presentation of the results of spot assays for monitoring 





Figure 3.15. Effect of LCA added at different periods of chronological lifespan on the 
ability of yeast to resist chronic osmotic stress. Wild-type yeast cells were cultured in YP 
medium initially containing 0.2% glucose, and LCA was added at the final concentration 
of 50 µM to a cell culture immediately following cell inoculation into the medium (on 
day 0) or on day 1, 2, 3, 5, 7, 9, 11 or 14 of cell culturing in this medium. The final 
concentration of DMSO in yeast cultures supplemented with LCA (and in the 
corresponding control cultures supplemented with compound vehicle) was 1% (v/v). Spot 
assays for monitoring osmotic stress resistance were performed as described in 
“Materials and Methods”. Serial ten-fold dilutions of cells were spotted on plates with 
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solid YP medium containing 2% glucose as carbon source and 1 M sorbitol. All pictures 







Figure 3.16. LCA differentially influences a longevity-extending process of the 
development of resistance to chronic osmotic stress if added at different periods of yeast 
chronological lifespan. A graphic presentation of the results of spot assays for monitoring 




Figure 3.17. A mechanism that may link the ability of LCA to extend longevity of CR 
yeast only if added at period 1 or 3 of chronological lifespan to the differential effects of 
this compound on certain longevity-extending and longevity-shortening processes 
controlled at different lifespan periods. LCA may control these longevity-defining 
processes at the checkpoints A, B and C that exist in L/D (period 1), PD (period 2) and 




Our analysis of how the addition of LCA to CR yeast at different periods of 
chronological lifespan influences several longevity-extending and longevity-shortening 
processes suggests a mechanism that may link the ability of LCA to increase the lifespan 
of CR yeast only if added at period 1 or 3 to its differential effects on a monitored in this 
study set of longevity-defining processes controlled at different lifespan periods (Figure 
3.17). In this mechanism, LCA added to CR yeast at period 1 increases chronological 
lifespan because (1) its addition at this period has a beneficial effect on six longevity- 
defining processes; (2) the longevity-extending effect of added at this period LCA on 
each of these processes persists through the entire lifespan, long after this critical lifespan 
period ended; and (3) the addition of LCA at this period does not cause a lifespan- 
shortening effect on any of the longevity-defining processes monitored in this study 
(Figure 3.17). Furthermore, although the addition of LCA at period 2 imposes a lifelong 
beneficial effect on two longevity-defining cellular process (i.e., it enhances cell 
resistance to mitochondria-controlled apoptotic death and stimulates mitochondrial 
genome maintenance), the observed inability of the compound to extend longevity if 
added at this period of lifespan could be due to the two enduring longevity-shortening 
effects that LCA exhibits following its addition at period 2 (Figure 3.17). These 
detrimental to longevity effects of LCA added at period 2 include a lifelong reduction of 
cell resistance to palmitoleic acid-induced necrotic death and a long-term decline of the 
efficacy with which the integrity of nuclear genome is maintained (Figure 3.17). In the 
mechanism that we propose here, LCA added to CR yeast at period 3 increases 
chronological lifespan because (1) its addition at this period has a beneficial effect on five 
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longevity-defining processes for the rest of the lifespan; and (2) the addition of LCA at 
this period does not cause a lifespan-shortening effect on any of the longevity-defining 
processes that we monitored (Figure 3.17). Moreover, the observed lack of an effect of 
LCA on a monitored set of longevity-defining processes following its addition at period 4 
may satisfactorily explain the inability of LCA to extend longevity if added at this 
lifespan period (Figure 3.17). 
 
Our model for a mechanism that may link the ability of LCA to increase the 
lifespan of CR yeast only if added at period 1 or 3 to its differential effects on several 
longevity-defining processes also foresees that LCA controls these processes at the 
checkpoints A, B and C that exist in L/D (period 1), PD (period 2) and early ST (period 
3) phases, respectively (Figure 3.17). It is conceivable that at each of these checkpoints 
LCA modulates the key set of longevity-defining cellular processes (modules) that 
comprise a biomolecular longevity network and are monitored by certain master 
regulators of the longevity control system. Based on the information gathered and 
processed by the master regulators, they modulate certain longevity-defining processes 
within monitored modules of the longevity network in order to limit the age-related 
accumulation of molecular and cellular damage. The resulting changes in the dynamics of 
individual modules constituting the network and in its general configuration are critically 
important for establishing the rate of cellular aging and, thus, define longevity. 
As outlined below, recent studies support the validity of the proposed here 
hypothesis on a stepwise progression of a biomolecular longevity network through a 
series of checkpoints, at each of which (1) some genetic, dietary and pharmacological 
anti-aging interventions modulate certain longevity-defining processes within modules 
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comprising the longevity network; and (2) some checkpoint-specific master regulators 
monitor and govern the functional states of these critical network modules. 
Studies in chronologically aging yeast revealed that, by promoting coupled 
respiration in mitochondria, elevating the mitochondrial membrane potential and 
increasing mitochondrial ROS production during L phase, a CR diet and some 
pharmacological interventions extend longevity by causing changes in several longevity- 
defining processes during the subsequent D, PD and ST phases. These changes include 
(1) increased intracellular levels of trehalose and glycogen, the two major glucose stores 
of yeast; (2) a remodeling of lipid metabolism in the endoplasmic reticulum, lipid bodies 
and peroxisomes; (3) reduced cell susceptibility to age-related forms of mitochondria- 
controlled apoptotic and lipid-induced necrotic death; (4) an attenuation of mitochondrial 
fragmentation; (5) a reduction in the mitochondrial membrane potential and 
mitochondrial ROS production; (6) elevated stability of nuclear and mitochondrial 
genomes; and (7) enhanced resistance to chronic oxidative and thermal stresses [14, 24, 
186 - 189]. It seems that in chronologically aging yeast TORC1 operates as one of the 
predicted by our hypothesis checkpoint-specific master regulators that at a checkpoint in 
L phase can monitor and govern a functional state of mitochondria [186 - 189]. 
Furthermore, recent studies in chronologically aging yeast suggest the existence of two 
checkpoints at which the intracellular level of trehalose defines longevity by modulating 
cellular proteostasis throughout lifespan [24, 190]. At one of these lifespan checkpoints in 
PD phase, trehalose operates as an anti-aging compound that (1) stabilizes the native state 
of proteins and thereby reduces the formation of their aberrantly folded species; (2) 
reduces the formation of insoluble protein aggregates by shielding the contiguous 
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exposed hydrophobic side chains of amino acids that are abundant in misfolded, partially 
folded and unfolded protein species and promote their aggregation; and (3) protects 
cellular proteins from oxidative carbonylation by interacting with their carbonylation- 
prone misfolded and unfolded species [190]. At another lifespan checkpoint in ST phase, 
trehalose functions as a pro-aging compound that shields the contiguous exposed 
hydrophobic side chains of amino acids abundant in misfolded, partially folded and 
unfolded protein species. By competing with molecular chaperones for binding with these 
patches of hydrophobic amino acid residues, trehalose interferes with the essential 
longevity-extending process of chaperone-assisted refolding of aberrantly folded protein 
species [190]. 
Moreover, as it has been mentioned in the “Introduction” section, studies in the 
nematode C. elegans provided evidence that UBL-5/DVE-1, DAF-16 and PHA-4 operate 
as the checkpoint-specific master regulators of longevity by governing progression 
through the three consecutive checkpoints operating during the L3/L4 larval stage of 
development, early adulthood and late adulthood, respectively [163 - 169]. 
Taken together, these findings support the view that aging in organisms across 
phyla is the final step of a developmental program whose progression through several 
lifespan checkpoints in a genotype-specific fashion is modulated by environmental cues 
(such as caloric and dietary intake, environmental stresses, endocrine factors, etc.) and is 
both monitored and governed by an evolutionarily conserved set of checkpoint-specific 
master regulators. Other data supporting this view have been comprehensively discussed 
elsewhere [24, 62, 64, 115, 174, 190 - 195]. 
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The major challenge now is to get a greater insight into mechanisms that in 
chronologically aging yeast underlie (1) a stepwise progression of the biomolecular 
longevity network through a series of checkpoints; (2) a modulation of various longevity- 
defining processes comprising the longevity network by genetic, dietary and 
pharmacological anti-aging interventions administered at different checkpoints; and (3) a 
monitoring of these longevity-defining processes at each checkpoint by specific master 
regulators. To address this challenge, several important questions need to be answered. 
How will genetic, dietary and pharmacological anti-aging interventions known to directly 
target specific longevity-extending or longevity-shortening processes alter the age-related 
dynamics of changes in the proteomes, lipidomes and metabolomes of chronologically 
aging yeast? How will these interventions affect the chronology of other longevity- 
defining processes that comprise the longevity network but are known not to be directly 
modulated by these interventions? How will genetic and pharmacological anti-aging 
interventions that specifically modulate the functional states of several currently known 
master regulators of yeast longevity influence a timeline of changes in the proteomes, 
lipidomes and metabolomes of chronologically aging yeast and what will be their effects 
on the age-related dynamics of various longevity-defining processes comprising the 
longevity network? We shall have to answer these important questions if we want to 
understand the complexity of the biomolecular network whose progression through a 
series of checkpoints is modulated by various environmental cues and is governed by 
checkpoints-specific master regulators. 
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4 A mitochondrially targeted compound delays aging in yeast through a 
mechanism linking mitochondrial membrane lipid metabolism to 






A body of evidence supports the notion that mitochondria regulate cellular aging 
in evolutionarily distant eukaryotic organisms [20, 196, 197]. These organelles 
compartmentalize various redox processes known to be essential for establishing the rate 
of cellular and organismal aging. Such longevity-defining redox processes in 
mitochondria include the coupling of electron transport to ATP synthesis, modulation of 
mitochondrial membrane potential, maintenance of cellular homeostasis of reactive 
oxygen species (ROS), and formation and release of certain metabolites and 
macromolecules that can set off a pro- or anti-aging cellular pattern [18, 20, 188, 198 - 
202]. Several small molecules have been shown to delay cellular and organismal aging in 
eukaryotes across phyla by modulating some of the mitochondria-confined redox 
processes. After being sorted to the mitochondrial matrix, the inner mitochondrial 
membrane (IMM) or the outer mitochondrial membrane (OMM), these anti-aging 
pharmaceuticals act as rechargeable antioxidants that attenuate oxidative damage to 




4.2 Results and Discussion 
 
Our recent study revealed a previously unknown mechanism of delaying cellular 
aging by a mitochondrially targeted natural compound which specifically impacts 
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mitochondrial redox biology [210]. The name of this compound is lithocholic acid (LCA), 
a bile acid which we identified in a high-throughput chemical genetic screen for small 
molecules extending longevity of chronologically aging yeast [14]. In the mechanism that 
we discovered, an exogenously added LCA enters yeast cells and accumulates mostly in 
the IMM; a minor portion of this bile acid is also confined to the OMM (Figure 4.1). The 
accumulated in both mitochondrial membranes pools of LCA elicit an age-related 
remodeling of phospholipid synthesis and movement within the IMM and OMM (Figure 
4.1). Such specific remodeling of mitochondrial phospholipid 
dynamics progresses with the chronological age of a yeast cell and ultimately causes 
significant changes in mitochondrial membrane lipidome. These changes include: (1) a 
decrease in the relative levels of phosphatidylethanolamine (PE), cardiolipin (CL) and 
monolysocardiolipin (MLCL) within mitochondrial membranes; and (2) an increase in 
the relative levels of phosphatidic acid (PA), phosphatidylserine (PS), 
phosphatidylcholine (PC) and phosphatidylglycerol (PG) within mitochondrial 
membranes (Figure 4.1). In turn, the LCA-driven changes in the composition of 
mitochondrial membrane phospholipids cause: (1) a substantial enlargement of 
mitochondria; (2) a significant decrease in mitochondrial number; (3) a reduction in the 
fraction of mitochondria with cristae extending from the IMM; and (4) a build-up within 
the mitochondrial matrix of abundant cristae disconnected from the IMM (Figure 4.1). 
These elicited by LCA major alterations in mitochondrial abundance and morphology in 
turn cause specific changes in the age-related chronology of such longevity-defining 




Figure 4.1. A mechanism of delaying aging in yeast by a mitochondrially targeted 
compound which impacts mitochondrial redox biology. Lithocholic bile acid (LCA) 
enters yeast cells, accumulates mainly in the inner mitochondrial membrane, and elicits a 
remodeling of phospholipid synthesis and movement within both mitochondrial 
membranes. Such remodeling of mitochondrial phospholipid dynamics causes changes in 
mitochondrial membrane lipidome. These changes in the composition of membrane 
phospholipids alter mitochondrial abundance and morphology, thereby triggering 
changes in the age-related chronology of several longevity-defining redox processes 
confined to mitochondria. For additional details, see text. 
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mitochondrial membrane potential, the preservation of cellular homeostasis of 
mitochondrially produced ROS, and the coupling of electron transport to ATP synthesis 
(Figure 4.1). The elevated efficiencies of mitochondrial respiration, membrane potential 
maintenance and ATP synthesis observed in chronologically “old”,  quiescent yeast 
cultured with LCA (as compared to those in age-matched cells cultured without LCA) are 
known to delay aging of yeast cells by increasing their long-term viability [14, 24, 186, 
187, 189, 210]. Furthermore, the raised sub-lethal concentration of mitochondria- 
generated intracellular ROS detected in this yeast (Figure 4.1) has been demonstrated to 
delay cellular aging because it stimulates a signaling network promoting the long-term 
stress resistance of yeast cells [14, 24, 186, 188, 199, 200, 210]. Importantly, the 
longevity-extending pattern of mitochondrial redox processes characteristic of 
chronologically “old”, quiescent yeast cultured with LCA (Figure 4.1) is likely due to the 
lowered below a toxic threshold intracellular concentration of ROS seen in 
chronologically “young”, non-quiescent yeast cultured in the presence of this bile acid 
[14, 210]. Indeed, a reduced ROS level in chronologically “young” yeast cells exposed to 
certain anti-aging interventions has been shown to lessen the extent of oxidative damage 
to mitochondrial macromolecules in these cells, thereby allowing them to maintain the 
functionality of macromolecules involved in mitochondrial respiration, membrane 
potential maintenance and ATP synthesis when these cells become chronologically “old” 
[14, 24, 189, 210]. Ultimately, the elicited by LCA changes in the age-related chronology 
of these mitochondrial redox processes extend longevity of chronologically aging yeast. 
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5 Interspecies chemical signals released into the environment may create 
xenohormetic, hormetic and cytostatic selective forces that drive the 






Aging of multicellular and unicellular eukaryotic organisms is a highly complex 
biological phenomenon, which affects numerous processes within cells [1, 49, 211, 212]. 
These cellular processes include cell cycle, cell growth, stress response, protein folding, 
apoptosis, autophagy, proteasomal protein degradation, actin organization, signal 
transduction, nuclear DNA replication, chromatin assembly and maintenance, ribosome 
biogenesis and translation, lipid and carbohydrate metabolism, oxidative metabolism in 
mitochondria, NAD+ homeostasis, amino acid biosynthesis and degradation, and 
 
ammonium and amino acid uptake [2, 50, 51, 213, 214]. Across phyla, such plethora of 
longevity-defining processes is governed by a nutrient signaling network integrating the 
AMP-activated protein kinase/target of rapamycin (AMPK/TOR), cAMP/protein kinase 
A (cAMP/PKA) and insulin/insulin-like growth factor 1 (IGF-1) pathways, as well as a 
sirtuin-governed protein deacetylation module [1, 50, 51, 146, 215, 216]. Because this 
evolutionarily conserved signaling network regulates longevity only in response to 
certain changes in the organismal and intracellular nutrient and energy status, it is 
“adaptable” by its nature [14]. By altering the organismal and intracellular nutrient and 
energy status, caloric restriction and dietary restriction extend longevity and improve 
health across species by modulating the adaptable longevity network [1, 55 - 57, 59, 217]. 
Unlike signaling pathways and sirtuin-governed protein deacetylation module integrated 
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into the adaptable longevity network, some longevity-defining pathways are 
 
“constitutive” or “housekeeping” by their nature as they regulate longevity irrespective of 
 
the organismal and intracellular nutrient status [14]. 
 
It should be stressed that both adaptable and housekeeping longevity pathways are 
the targets of longevity-extending and health-improving small molecules that are 
produced and then released into the environment by organisms from all domains of life 
(i.e., bacteria, fungi, plants and animals) within an ecosystem. We therefore propose a 
hypothesis in which interspecies chemical signals released into the environment create 
xenohormetic, hormetic and cytostatic selective forces that drive the ecosystemic 






5.2.1 Plants and other autotrophs release into the environment xenohormetic and 
cytostatic interspecies chemical signals that extend longevity of other 
organisms within an ecosystem 
According to the “xenohormesis” hypothesis of Howitz and Sinclair, in response 
to various hormetic environmental stresses - such as UV light, dehydration, infection, 
predation, cellular damage and nutrient deprivation - plants and other autotrophic 
organisms synthesize a group of secondary metabolites called xenohormetic 
phytochemicals [47, 48, 218]. Prior to being released into the environment, these 
secondary metabolites activate defense systems protecting the host autotrophic organisms 
against hormetic environmental stresses that caused their synthesis [48, 218]. After being 
released into the environment, these xenohormetic phytochemicals provide benefits to 
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health and longevity of heterotrophic organisms within the ecosystem. It was proposed 
that xenohormetic phytochemicals cause such life-extending and health-improving effects 
not by operating as mildly toxic hormetic molecules, but by activating the key enzymes 
of stress-response, anti-aging pathways known to govern longevity-related processes in 
heterotrophic organisms [47, 48, 218]. Recent studies revealed that some xenohormetic 
phytochemicals, such as resveratrol and caffeine, extend longevity of heterotrophic 
organisms by attenuating the adaptable TOR signaling pathway known to accelerate their 
aging [64, 219 - 222]. Because the TOR pathway also plays a pivotal role in promoting 
proliferative growth of all heterotrophic organisms, resveratrol and caffeine exhibit a 
cytostatic effect in these organisms [64, 174, 195, 222]. 
By extending the xenohormesis hypothesis of Howitz and Sinclair, we propose that 
within each of the heterotrophic species composing an ecosystem there are organisms that 
(1) possess the most effective (as compared to their counterparts of the same species) 
mechanisms for sensing xenohormetic and cytostatic phytochemicals released into the 
environment by autotrophic species; and (2) can respond to these phytochemicals by 
activating the key enzymes of stress-response, anti-aging pathways and/or by attenuating 
the adaptable, pro-aging TOR signaling pathway - thereby undergoing life-extending 
changes to their metabolism and physiology. These heterotrophic organisms are expected 
to live longer then their counterparts within the same species. Thus, their ability to sense 
the longevity-extending xenohormetic and cytostatic phytochemicals released into the 
environment by autotrophic species and to respond to these phytochemicals by 
undergoing certain life-extending metabolic and physiological changes will: (1) increase 
their chances of survival; (2) create selective forces aimed at maintaining such ability; 
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5.2.2 Mammals release into the environment bile acids, hormetic interspecies 
chemical signals that extend longevity of yeast and perhaps of other 
organisms within an ecosystem 
In mammals, bile acids operate not only as trophic factors for the enteric 
epithelium and detergents for the emulsification and absorption of dietary lipids, but also 
as signaling molecules regulating lipid, glucose and energy homeostasis and activating 
detoxification of xenobiotics [223 - 228]. Bile acids have been shown to cause numerous 
health-improving metabolic effects in mammals and to protect them from xenobiotic 
toxins [223 - 228]. Therefore, it was proposed that by promoting chemical hormesis in 
mammals, bile acids – mildly toxic molecules with detergent-like properties – may 
extend their longevity by acting as endobiotic regulators of aging [185, 229 - 231]. 
Importantly, our recent study identified lithocholic acid, a bile acid, as an anti-aging 
compound that extends yeast longevity by activating a compendium of anti-aging 
processes and attenuating a distinct set of pro-aging processes [14]. Unlike mammals, 
yeast do not synthesize bile acids [14, 227]. We therefore propose that bile acids released 
into the environment by mammals may act as interspecies chemical signals extending 
longevity of yeast species and, perhaps, of other organisms that can: (1) sense these 
mildly toxic molecules with detergent-like properties; and (2) respond to the resulting 
mild cellular damage by developing the most efficient stress protective mechanisms. We 
hypothesize that such mechanisms may provide effective protection of yeast and other 
organisms not only against cellular damage caused by bile acids but also against 
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molecular and cellular damage accumulated with age. Thus, those species of the 
organisms within an ecosystem that that have been selected for the most effective (as 
compared to their counterparts of the same species) mechanisms providing protection 
against bile acids are expected to (1) live longer than their counterparts within the same 
species; and (2) evolve the most effective anti-aging mechanisms that are sensitive to 
regulation by bile acids. Thus, the ability of certain non-mammalian species within an 
ecosystem to sense bile acids produced by mammals and then to respond by undergoing 
certain longevity-extending changes to their physiology will increase their chances of 
survival - thereby creating selective force aimed at maintaining such ability and driving 




5.2.3 Soil bacteria release into the environment rapamycin, a cytostatic 
interspecies chemical signal that extends longevity of other organisms within 
an ecosystem 
The adaptable TOR signaling pathway can be attenuated not only by resveratrol 
and spermidine - the two longevity-extending xenohormetic and cytostatic 
phytochemicals released into the environment by autotrophic species – but also by 
rapamycin [174, 234, 235]. Rapamycin - a macrocyclic lactone synthesized by soil 
bacteria to inhibit growth of fungal competitors - extends longevity of yeast, fruit flies 
and mice by specifically inhibiting the nutrient-sensory protein kinase TOR, a master 
negative regulator of the pro-aging TOR signaling pathway [79, 173, 174, 235, 236]. 
Rapamycin exhibits a potent cytostatic effect by causing G1 cell cycle arrest and greatly 
delaying proliferative growth of organisms across phyla [174, 234 - 236]. We therefore 
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hypothesize that rapamycin released into the environment by soil bacteria not only 
suppresses growth of fungal competitors, but may also may create selective pressure for 
the evolution of yeast, fruit fly and mammalian species that can respond to rapamycin- 
induced growth retardation by developing certain mechanisms aimed at such remodeling 
of their anabolic and catabolic processes that would increase their chances of survival 
under conditions of slow growth. We propose that some of these mechanisms delay aging 
by optimizing essential longevity-related processes and remain sensitive to modulation by 
rapamycin. Therefore, the ability of yeast, fruit fly and mammalian species within an 
ecosystem to sense rapamycin produced by soil bacteria and then to respond by 
undergoing certain life-extending changes to their metabolism and physiology will 
increase their chances of survival - thereby creating selective force aimed at maintaining 




5.2.4 A hypothesis of the xenohormetic, hormetic and cytostatic selective forces 
that drive the ecosystemic evolution of longevity regulation mechanisms 
Our analysis of how several small molecules synthesized and released into the 
environment by one species of the organisms composing an ecosystem extend longevity 
of other species within this ecosystem suggests a hypothesis in which these interspecies 
chemical signals create xenohormetic, hormetic and cytostatic selective forces that drive 
the ecosystemic evolution of longevity regulation mechanisms. In our hypothesis, after 
being released into the environment by one species of organisms capable of synthesizing 
such small molecules, they can activate anti-aging processes and/or inhibit pro-aging 
processes in other species within an ecosystem. Within each of these other species, there 
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are organisms that possess the most effective (as compared to their counterparts of the 
same species) mechanisms for sensing the interspecies chemical signals and for 
responding to such signals by undergoing certain life-extending changes to their 
metabolism and physiology; such life-extending changes could be hormetic and/or 
cytostatic by their nature. These organisms therefore are expected to live longer than their 
counterparts of the same species within the ecosystem. Thus, the ability of a species of 
the organisms composing an ecosystem to sense the longevity-modulating interspecies 
chemical signals released into the environment by other species within the ecosystem and 
to respond to these signals by undergoing certain life-extending metabolic and 
physiological changes is expected to increase its chances to survive, thereby creating 
selective force aimed at maintaining such ability. Our hypothesis implies that the 
evolution of longevity regulation mechanisms in each species of the organisms 
composing an ecosystem is driven by the ability of this species to undergo specific life- 
extending metabolic or physiological changes in response to hormetic or cytostatic 
chemical compounds that are released to the ecosystem by other species. 
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6 LCA suppresses mitochondrial deficiency known to cause a neurological 






Mitochondrial encephalomyopathies in humans are caused by cytochrome c 
oxidase (COX; respiratory complex IV) deficiency [237, 238]. Two major causes of COX 
deficiency in humans (and in the budding yeast Saccharomyces cerevisiae) are: (1) 
defects in mitochondrial translation of the mitochondrial DNA (mtDNA)-encoded Cox1p, 
Cox2p and Cox3p subunits of COX; and (2) defects in the assembly of COX within the 
mitochondrial inner membrane from the three subunits encoded by mtDNA and many 
subunits encoded by nuclear genes (Figures 6.1 and 6.2) [237 - 239]. Both these causes of 
COX deficiency in humans (and yeast) are due to mutations in nuclear genes. Several 
human translation and assembly factors for COX that have been implicated in 
mitochondrial encephalomyopathies have been shown to have yeast orthologues, 
including: (1) yeast Hah1p is an orthologue of human TACO1 implicated in the late- 
onset Leigh syndrome [238, 240]; (2) yeast Pet309p is an orthologue of human LRPPRC 
implicated in the French-Canadian variant of Leigh syndrome [238, 241, 242]; (3) yeast 
Shy1p is an orthologue of human SURF1 implicated in the Leigh syndrome [238, 243, 
244]; and (4) yeast Sco1p is an orthologue of human SCO1 implicated in a mitochondrial 




Figure 6.1. A stepwise assembly of the COX complex from three mitochondrial DNA 
(mtDNA)-encoded subunits (Cox1p, -2p and -3p) and eight nuclear DNA (nDNA)- 







Figure 6.2. A model for the translation of Cox1p and assembly of the entire COX 





Figure 6.3. Several human translation and assembly factors for COX that have been 
implicated in mitochondrial encephalomyopathies have yeast orthologues. From: 











Primary cell lines were established from subject skin fibroblasts. The subject and control 
cell lines were immortalized by transduction with a retroviral vector expressing the HPV- 
16 E7 gene plus a retroviral vector expressing the catalytic component of human 
telomerase (htert). The fibroblasts and HEK 293 line were grown at 37 °C in an 




Electrophoresis and immunobloting 
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Blue-Native polyacrylamide gradient electrophoresis (BN-PAGE) was used to separate 
samples in the first dimension on 6-15% polyacrylamide gradient gel. Mitoplasts were 
prepared from fibroblasts by treatment with 0.8 mg of digitonin/mg of protein and 
solubilized with 1% lauryl maltoside; 20 µg of the solubilized proteins were used for 
electrophoresis. Individual structural subunits of complexes I, II, III, IV and V were 





RNA blot analysis 
 
RNA from subject and control fibroblasts was isolated using the RNeasy Kit (Qiagen). 10 
 
µg of total RNA were separated on a denaturing MOPS/formaldehyde agarose gel and 
transferred to a nylon membrane. 300- to 500-bp-long PCR products of individual 
mitochondrial genes were labeled with [α-32P]-dCTP (GE Healthcare) using the 
MegaPrime DNA labeling kit (GE Healthcare). Hybridization was conducted according 
to the manufacturer's manual using ExpressHyb Hybridization Solution (Clontech) and 




TACO1 antibody production 
 
A polyclonal antibody against two peptides (Ac-IKGPKDVERSRIFSKLC-amide and 
Ac-LEFIPNSKVQLAEPDLEQAAC-amide) from the human TACO1 protein was 
prepared by 21st Century Biochemicals (Marlboro, Massachusetts). Crude serum and 
affinity purified antibodies were tested on cell lines overexpressing TACO1 protein and 
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detected a band of approximately 28 kDa. The C-terminal affinity-purified antibody was 






Fibroblasts were resuspended in ice-cold 250 mM sucrose/10 mM Tris-HCl/1 mM EDTA 
(pH 7.4) and homogenized with 10 passes through a pre-chilled, zero clearance 
homogenizer (Kimble/Kontes). Samples were centrifuged twice for 10 min at 600 x g to 
obtain a postnuclear supernatant. Mitochondria were pelleted by centrifugation for 10 





Yeast strains and media 
 
 
The wild-type strain Saccharomyces cerevisiae BY4742 (MAT α his3∆1 leu2∆0 lys2∆0 
ura3∆0) and mutant strains pet100∆ (MAT α his3∆1 leu2∆0 lys2∆0 ura3∆0 
pet100∆::kanMX4), hah1∆ (MAT α his3∆1 leu2∆0 lys2∆0 ura3∆0 hah1∆::kanMX4), 
pet309∆ (MAT α his3∆1 leu2∆0 lys2∆0 ura3∆0 pet309∆::kanMX4), mss51∆ (MAT α 
his3∆1 leu2∆0 lys2∆0 ura3∆0 mss51∆::kanMX4), sco1∆ (MAT α his3∆1 leu2∆0 lys2∆0 
ura3∆0 sco1∆::kanMX4), shy1∆ (MAT α his3∆1 leu2∆0 lys2∆0 ura3∆0 shy1∆::kanMX4), 
were used in this study. Media components were as follows: (1) YEPD (0.2% glucose), 
1% yeast extract, 2% peptone, 0.2% glucose; and (2) YEPD (2% glucose), 1% yeast 
 
extract, 2% peptone, 2% glucose. 
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A plating assay for the analysis of chronological lifespan 
 
 
Cells were grown in YEPD (0.2% glucose) medium at 30oC with rotational shaking at 
 
200 rpm in Erlenmeyer flasks at a flask volume/medium volume ratio of 5:1. A sample of 
cells was removed from each culture at various time points. A fraction of the cell sample 
was diluted in order to determine the total number of cells per ml of culture using a 
hemacytometer. 10 μ l of serial dilutions (1:10 to 1:103) of cells were applied to the 
hemacytometer, where each large square is calibrated to hold 0.1 μ l. The number of cells 
in 4 large squares was then counted and an average was taken in order to ensure greater 
accuracy. The concentration of cells was calculated as follows: number of cells per large 
square x dilution factor x 10 x 1,000 = total number of cells per ml of culture. A second 
fraction of the cell sample was diluted and serial dilutions (1:102 to 1:105) of cells were 
 
plated onto YEPD (2% glucose) plates in triplicate in order to count the number of viable 
cells per ml of each culture. 100 μ l of diluted culture was plated onto each plate. After a 
48-h incubation at 30oC, the number of colonies per plate was counted. The number of 
 
colony forming units (CFU) equals to the number of viable cells in a sample. Therefore, 
the number of viable cells was calculated as follows: number of colonies x dilution factor 
x 10 = number of viable cells per ml. For each culture assayed, % viability of the cells 
was calculated as follows: number of viable cells per ml / total number of cells per ml x 
100%. The % viability of cells in mid-logarithmic phase was set at 100% viability for that 
particular culture. The life span curves for wild-type and some of the mutant strains were 
also validated using a LIVE/DEAD yeast viability kit (Invitrogen) following the 
manufacturer's instructions for stationary-phase cultures. 
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Pharmacological manipulation of chronological lifespan 
 
Chronological lifespan analysis was performed as described above in this section. The 
lithocholic (LCA) [#L6250] bile acid was from Sigma. The stock solution of LCA in 
DMSO was made on the day of adding this compound to cell cultures. LCA was added to 
growth medium at the final concentration of 50 µM immediately following cell 
inoculation into the medium. The final concentration of DMSO in yeast cultures 
supplemented with LCA (and in the corresponding control cultures supplemented with 






Statistical analysis was performed using Microsoft Excel’s (2010) Analysis ToolPack- 
VBA. All data are presented as mean ± SEM. The p values were calculated using an 









6.3.1 LCA can extend longevity of yeast mutants lacking some orthologues of 
human genes implicated in mitochondrial encephalomyopathies 
Currently, there are no small molecules known to rescue or alleviate any of the 
human mitochondrial encephalomyopathies on the organismal or cellular (i.e., in cultured 
human cells) level. Our recent unpublished findings revealed that LCA, a potent 
longevity-extending natural compound that delays cellular aging in yeast [14], stimulates 
mitochondrial protein translation and elevates the levels of mitochondrial protein 
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assembly factors in yeast cells. Therefore, we sought to investigate if LCA can extend 
longevity of yeast mutants lacking orthologues of human genes implicated in 
mitochondrial encephalomyopathies. We first tested how LCA influences the 
chronological lifespan of the hah1Δ mutant grown under CR conditions on 0.2% glucose. 
This mutant is considered as a yeast model of the human late-onset Leigh syndrome, a 
human neurological disorder that is caused by a recessive mutation in TACO1 gene 
(Figure 6.3) [238, 240]. We found that under CR conditions LCA extends both the mean 
and maximal lifespans of the hah1Δ mutant to a greater degree than that of wild-type 






Figure 6.4. LCA extends longevity of the hah1∆ mutant (a yeast model of the human 
late-onset Leigh syndrome) to a greater degree than that of WT strain. Yeast cells were 
grown in YEPD medium containing 0.2% glucose as a carbon source, with or without 
LCA. The final concentration of LCA was 50 μM. 
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The pet309∆ mutant of yeast has been shown to be a model of the human French- 
Canadian variant of Leigh syndrome (Figure 6.3) [238, 241, 242]. We found that LCA 






Figure 6.5. LCA does not extend longevity of the pet309Δ mutant, a yeast model of the 
human French-Canadian variant of Leigh syndrome. Yeast cells were grown in YEPD 
medium containing 0.2% glucose as a carbon source, with or without LCA. The final 




We also found that under CR conditions LCA does not extend longevity of the 
mss51∆ mutant, which is impaired in the same step of COX assembly as yeast models of 




Figure 6.6. LCA does not extend longevity of the mss51Δ mutant, a yeast model of the 
Leigh syndrome and its French-Canadian variant. Yeast cells were grown in YEPD 
medium containing 0.2% glucose as a carbon source, with or without LCA. The final 




The sco1∆ mutant of yeast has been shown to be a model of one of the 
mitochondrial encephalomyopathies called severe COX deficiency [238, 245, 246]. As 
we found, under CR conditions LCA extends both the mean and maximal chronological 







Figure 6.7. Under CR conditions LCA extends both the mean and maximal chronological 
lifespans of the sco1Δ mutant to a greater degree than that of WT strain. Yeast cells were 
grown in YEPD medium containing 0.2% glucose as a carbon source, with or without 




Our evaluation of the effect of LCA on the chronological lifespan of the shy1∆ 
mutant, a yeast model of the Leigh syndrome [238, 243, 244], revealed that LCA does 




Figure 6.8. Under CR conditions LCA does not extend longevity of the shy1Δ mutant, a 
yeast model of the Leigh syndrome. Yeast cells were grown in YEPD medium containing 
0.2% glucose as a carbon source, with or without LCA. The final concentration of LCA 
 





We then assessed how LCA influences longevity of the pet100∆ mutant of yeast, 
which is impaired in the same step of COX assembly as yeast models of the Leigh 
syndrome and severe COX deficiency [238]. We found that LCA does not extend 




Figure 6.9. Under CR conditions LCA does not extend longevity of the pet100∆ mutant, 
which is impaired in the same step of COX assembly as yeast models of the Leigh 
syndrome and severe COX deficiency. Yeast cells were grown in YEPD medium 
containing 0.2% glucose as a carbon source, with or without LCA. The final 




6.3.2 LCA can suppress mitochondrial COX deficiency causing Leigh syndrome, a 
human neurological disorder caused by a mutation in TACO1 gene 
Because our findings revealed that LCA extends both the mean and maximal 
chronological lifespans of the hah1∆ mutant (a yeast model of Leigh syndrome, a human 
neurological disorder caused by a recessive mutation in TACO1 gene; Figures 6.3 and 
6.4) to a greater degree than those of WT strain, we investigated if in cultured human 
fibroblasts of patients with this disorder LCA can suppress mitochondrial COX 
deficiency causing it. Human TACO1 protein is known to be encoded by nuclear DNA 
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and to operate as a translational activator of the mtDNA-encoded COX I subunit (Figure 
 
6.10) [238, 240]. Leigh syndrome is caused by a recessive mutation in TACO1 gene; this 
mutation is a one-base-pair insertion at position 472 (472insC) resulting in a frameshift 
and the creation of a premature stop codon (Figure 6.11) [240]. It has been demonstrated 
that this mutation in the TACO1 gene significantly reduces: (1) the steady-state level of 
TACO1 mRNA (due to its nonsense-mediated decay); (2) the rate of COX I synthesis; (3) 
the steady-state level of COX I; and (4) the steady-state levels of COX II, COX III and 







Figure 6.10. Human TACO1 protein is a translational activator of the mtDNA-encoded 
 




Figure 6.11. Leigh syndrome is caused by a recessive mutation in TACO1 gene; this 
mutation is a one-base-pair insertion at position 472 (472insC) resulting in a frameshift 






Figure 6.12. TACO1 mutations reduces the steady-state level of TACO1 mRNA, rate of 
COX I synthesis, steady-state level of COX I, and steady-state levels of COX II, COX III 




Using immunoblot analysis of purified mitochondria, we found that LCA greatly 
elevates the steady-state levels of the COX I, COX II and COX III subunits of the COX 
complex in mitochondria of a TACO1 subject (Figures 6.13 to 6.20). Our immunoblot 
analysis of purified mitochondria also revealed that significantly increases the steady- 
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state level of TACO1 protein in mitochondria of this TACO1 subject (Figures 6.21 and 
 
6.22). It should be stressed that anti-TACO1 antibody is known to recognize the C 
terminus of TACO1 protein [240]. We therefore concluded that LCA promotes synthesis 
of the full-length TACO1 protein. Based on these observations, we hypothesize that in 
TACO1 mutant cells, LCA restores the assembly of the mitochondrial COX complex by 
increasing the steady-state level of TACO1 protein, perhaps by any of the following 
mechanisms: (1) stabilizing mutant TACO1 mRNA by decelerating its nonsense- 
mediated decay; and/or (2) enabling ribosomal readthrough of premature but not normal 
termination codons [247 – 250]. 
 
 
Figure 6.13. LCA greatly elevates the steady-state level of the COX I subunit of the 
COX protein complex. Immunoblot analysis of COX I steady-state level in purified 
mitochondria (the complex II 70-kDa subunit was used as a loading control). 
 
 
Figure 6.14. LCA greatly elevates the steady-state level of the COX I subunit of the 
COX protein complex. Immunoblot analysis of COX I steady-state level in purified 




Figure 6.15. LCA greatly elevates the steady-state level of the COX II subunit of the 
COX protein complex. Immunoblot analysis of COX II steady-state level in purified 
mitochondria (the complex II 70-kDa subunit was used as a loading control). 
 
 
Figure 6.16. LCA greatly elevates the steady-state level of the COX II subunit of the 
COX protein complex. Immunoblot analysis of COX II steady-state level in purified 
mitochondria (the complex II 70-kDa subunit was used as a loading control; n = 2). 
 
 
Figure 6.17. LCA greatly elevates the steady-state level of the COX III subunit of the 
COX protein complex. Immunoblot analysis of COX III steady-state level in purified 




Figure 6.18. LCA greatly elevates the steady-state level of the COX III subunit of the 
COX protein complex. Immunoblot analysis of COX III steady-state level in purified 
mitochondria (the complex II 70-kDa subunit was used as a loading control; n = 2). 
 
 
Figure 6.19. LCA increases the steady-state level of the entire COX protein complex (the 
respiratory complex IV). BN-PAGE of purified mitochondria followed by immunoblot 





Figure 6.20. LCA increases the steady-state level of the entire COX protein complex (the 
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respiratory complex IV). BN-PAGE of purified mitochondria followed by immunoblot 






Figure 6.21. LCA increases the steady-state level of TACO1 protein. Immunoblot 
analysis of TACO1 steady-state level in purified mitochondria using an antibody that 
recognizes its C terminus (the complex II 70-kDa subunit was used as a loading control). 
 
 
Figure 6.22. LCA increases the steady-state level of TACO1 protein. Immunoblot 
analysis of TACO1 steady-state level in purified mitochondria using an antibody that 
recognizes its C terminus (the complex II 70-kDa subunit was used as a loading control; 
n = 6). 
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7 Suggestions for future work 
 
We demonstrated that LCA can suppress mitochondrial COX deficiency causing 
Leigh syndrome, a human neurological disorder caused by a recessive mutation in 
TACO1 gene. Our findings provided evidence that LCA promotes synthesis of the full- 
length TACO1 protein. Based on these observations, we put forward a hypothesis that in 
TACO1 mutant cells LCA restores the assembly of the mitochondrial COX complex by 
increasing the steady-state level of TACO1 protein, perhaps by any of the following 
mechanisms: (1) stabilizing mutant TACO1 mRNA by decelerating its nonsense- 
mediated decay; and/or (2) enabling ribosomal readthrough of premature but not normal 
termination codons [247 - 250]. A challenge now is to get a greater insight into these 
mechanisms. To address this challenge, many important questions need to be answered. 
Does LCA enter cultured human fibroblasts or does it activate a signaling pathway 
elevating the steady-state level of TACO1 protein? Does LCA increase the level of 
TACO1 mRNA in TACO1 mutant cells? Will gentamycin and/or PTC124 (the two 
known drugs enabling ribosomal readthrough of premature stop codons) be able to 
restore COX assembly in TACO1 mutant cells by increasing the steady-state level of 
TACO1 protein? If so, will various combinations of LCA, gentamycin and/or PTC124 be 
more efficient in restoring COX assembly in TACO1 mutant cells than any of these 
compounds alone? Will siRNA directed against UPF1 and/or UPF2 (the two proteins that 
in mammalian cells are known to function in destabilizing mRNAs carrying premature 
stop codons) be able to restore COX assembly in TACO1 mutant cells by increasing the 
steady-state level of TACO1 protein? 
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